COENZYME Q10

OTHER NAME(S):

Co Q10, Co Q-10, Coenzima Q-10, Co-Enzyme 10, Coenzyme Q 10, Coenzyme Q10, Co-Enzyme Q10, Co-Enzyme Q-10, Co-Q 10, CoQ10, Co-Q10, CoQ-10, Ubidcarenone, Ubidécarénone, Ubiquinone-10.<br/><br/>

Overview

Overview Information

Coenzyme Q10 is a vitamin-like substance found throughout the body, but especially in the heart, liver, kidney, and pancreas. It is eaten in small amounts in meats and seafood. Coenzyme Q10 can also be made in a laboratory.

Coenzyme Q10 is most commonly used for conditions that affect the heart such as heart failure, chest pain, and high blood pressure. It is also used for preventing migraine headache, Parkinson's disease, and many other conditions.

Coenzyme Q10 was first identified in 1957. The "Q10" refers to the chemical make-up of the substance.

How does it work?

Coenzyme Q10 is an important vitamin-like substance required for the proper function of many organs and chemical reactions in the body. It helps provide energy to cells. Coenzyme Q10 also seems to have antioxidant activity. People with certain diseases, such as heart failure, high blood pressure, gum disease, Parkinson's disease, certain diseases of the muscles, and HIV infection, might have lower levels of coenzyme Q10.

Uses

Uses & Effectiveness?

Likely Effective for

  • Coenzyme Q10 deficiency. Taking coenzyme Q10 by mouth seems to improve symptoms of coenzyme Q10 deficiency. This is a very rare condition. The symptoms include weakness, fatigue, and seizures.
  • Disorders that limit energy production in the cells of the body (mitochondrial disorders). Taking coenzyme Q10 by mouth seems to reduce symptoms of mitochondrial disorders. However, improvement in symptoms is slow. Some people have to take coenzyme Q10 for 6 months to get the most benefit.

Possibly Effective for

  • Age-related vision loss (age-related macular degeneration). Taking a specific product containing coenzyme Q-10, acetyl-L-carnitine, and omega-3 fatty acids (Phototrop) by mouth seems to improve vision in people with age-related vision loss.
  • Preventing death due to heart problems. Some research suggests that taking coenzyme Q10 along with selenium might reduce the chance of heart-related death in the elderly.
  • Heart failure. Early research found that heart failure might be linked with low coenzyme Q10 levels. Some research shows that taking coenzyme Q10 might help reduce some symptoms of heart failure. Coenzyme Q10 might also reduce the chances of having an abnormal heart rhythm related to heart failure. Some research suggests it works best in people who are not taking conventional medications for heart failure, such as an ACE inhibitor.
  • Nerve damage caused by diabetes (diabetic neuropathy). Research shows that taking coenzyme Q-10 improves nerve damage and nerve pain in people with nerve damage caused by diabetes.
  • Fibromyalgia. Some research show that taking coenzyme Q10 by mouth seems to reduce pain by over 50%, fatigue by 47%, morning tiredness by 56%, and tender points by 44% in people with fibromyalgia.
  • HIV/AIDS. Taking coenzyme Q10 by mouth seems to improve immune function in people with HIV/AIDS.
  • An inherited neurological disorder called Huntington's disease. Ubiquinol, an altered form of coenzyme Q10, has been granted "Orphan Drug Status" by the U.S. Food and Drug Administration (FDA). This gives the maker of Ubiquinol some financial incentives to study its effectiveness for Huntington's, a condition that is so rare (affecting less than 200,000 individuals) that pharmaceutical companies might not otherwise invest in developing a drug for it. However, taking coenzyme Q10 by mouth in doses of 600 mg daily or less does not seem to be effective for slowing the progression of Huntington's disease.
  • Blood vessel complications caused by heart bypass surgery. Reduced blood supply during heart or blood vessel surgery can deprive tissue of oxygen. When blood supply returns to this tissue, the tissue can become damaged. There is some evidence that taking coenzyme Q10 by mouth for at least one week before heart bypass surgery or blood vessel surgery might help to reduce tissue damage. However, not all research agrees with this finding.
  • A specific type of high blood pressure. Taking coenzyme Q10 by mouth daily appears to lower systolic blood pressure (the top number) in some people with high systolic blood pressure but normal diastolic blood pressure (the bottom number).
  • Migraine headache. Taking coenzyme Q10 by mouth seems to help prevent migraine headaches. Studies show it can decrease the frequency of headaches by about 30% and the number of days with headache-related nausea by about 45% in adults. More than half of patients taking coenzyme Q10 experience a 50% decrease in the number of headache days per month. Taking coenzyme Q10 also appears to reduce migraine frequency in children who have low levels of coenzyme Q10. It can take up to 3 months for significant benefit. However, coenzyme Q10 does not seem to be effective in treating migraines once they have developed.
  • A muscle disorder called muscular dystrophy. Taking coenzyme Q10 by mouth seems to improve physical performance in some people with muscular dystrophy.
  • Heart attack. When started within 72 hours of a heart attack and taken for one year, coenzyme Q10 appears to lower the risk of heart-related events, including another heart attack.
  • Painful erection in men (Peyronie's disease). Research shows that taking coenzyme Q10 improves erectile function in men with painful erections.

Possibly Ineffective for

  • Alzheimer's disease. Taking coenzyme Q10 does not seem to improve mental function in people with Alzheimer's disease.
  • Neurodegenerative disease called ALS or Lou Gehrig's disease. Research shows that taking coenzyme Q10 does not slow the progression of ALS.
  • Fatigue due to cancer drugs. Taking coenzyme Q10 does not seem to reduce - fatigue in people being treated for breast cancer.
  • Cocaine dependence. Taking a combination of coenzyme Q10 and L-carnitine does not reduce cocaine use.
  • High cholesterol. Taking coenzyme Q10 does not seem to reduce total cholesterol, triglycerides, or low-density lipoprotein (LDL or "bad") cholesterol, or increase high-density lipoprotein (HDL or "good") cholesterol.
  • Symptoms affecting polio survivors (post-polio syndrome). Research shows that taking coenzyme Q10 does not improve muscle strength or muscle function in people with post-polio syndrome.

Likely InEffective for

  • Athletic performance. Taking coenzyme Q10 by mouth, alone or with other ingredients, does not improve athletic performance in athletes or non-athletes.

Insufficient Evidence for

  • Chest pain (angina). Some early research suggests that taking coenzyme Q10 by mouth might reduce chest pain and improve exercise ability in people with angina.
  • Heart toxicity caused by cancer drugs. Early research suggests that taking coenzyme Q10 by mouth might protect the heart in children aged 3-12 years who are being treated with a class of drugs called anthracyclines. However, results from larger studies are inconsistent.
  • Asthma. Some early research suggests that taking a combination of coenzyme Q10, vitamin E (alpha-tocopherol), and vitamin C in addition to conventional asthma treatment reduces the dosage of drugs needed by people with mild-to-moderate asthma. However, it does not appear to improve lung function or reduce blockage of airways.
  • Autism. Early research shows that taking an specific form of coenzyme Q10 called ubiquinol improves autism symptoms in autism patients aged 3-6 years according to parent assessment. Higher quality studies are needed to confirm these results.
  • Mental health disorder of extreme mood swings (bipolar disorder). Early research shows that taking coenzyme Q10 improve symptoms of depression in people over 55 years of age with bipolar disorder.
  • Breast cancer. Some research in Chinese women suggests that having low blood levels of coenzyme Q10 is linked to an increased risk of breast cancer. Also, early research shows that taking coenzyme Q10 by mouth might be helpful in advanced breast cancer when used along with surgery and conventional treatment plus other antioxidants and omega-3 and omega-6 fatty acids. Higher quality studies are needed to confirm these results.
  • Cancer. Low coenzyme Q10 levels seem to be linked with an increased risk of skin cancer. Early research suggests that taking coenzyme Q10 along with other antioxidants increases survival time by 40% in patients with terminal cancer. Higher quality studies are needed to confirm these results.
  • Brain damage that affects muscle movement (cerebellar ataxia). Early research suggests that taking coenzyme Q10 by mouth can improve posture and muscle function in people with cerebellar ataxia and low coenzyme Q10 levels. However, it doesn't seem to benefit people with normal coenzyme Q10 levels.
  • Lung disease called chronic obstructive pulmonary disease (COPD). Early research suggests that taking coenzyme Q10 does not improve lung function or exercise performance in people with COPD.
  • Cyclic vomiting syndrome. Early research suggests that taking coenzyme Q10 might work as well as prescription medications used to treat cyclic vomiting syndrome.
  • Diabetes. Research about the effectiveness of coenzyme Q10 for diabetes is conflicting. Some research shows that taking coenzyme Q10 might lower blood sugar levels in people with type 2 diabetes. However, other research has found no benefit in people with type 1 or type 2 diabetes.
  • Weakened and enlarged heart (dilated cardiomyopathy). Early research suggests that taking coenzyme Q10 improves heart function in children with dilated cardiomyopathy.
  • Dry mouth. Early research suggests that taking an altered form of coenzyme Q10 called ubiquinol improves dry mouth.
  • Eye surgery. Research suggests that administering an eye solution containing coenzyme Q10 and vitamin E increases the speed of nerve regeneration after cataract eye surgery.
  • Rare inherited disease that causes nerve damage (Friedreich's ataxia). Some early research shows that taking coenzyme Q10 plus vitamin E improves heart function but not posture or manner of walking in in people with Friedreich's ataxia. However, other early research suggests that taking vitamin E together with coenzyme Q10 helps prevent decline in coordination, posture, and movement in people with Friedreich's ataxia compared to no treatment. Coenzyme Q10 seems to work best in patients with low coenzyme Q10 levels at baseline.
  • Hearing loss. Some research suggests that taking a specific coenzyme Q10 product (Q-TER) by mouth improves hearing in people with age-related hearing loss. However, combining coenzyme Q10 with conventional steroid treatments does not improve hearing more than steroid treatment alone in people with sudden deafness. Also, it doesn't appear to improve hearing in people with noise-induced hearing loss.
  • Hepatitis C. Research shows that taking coenzyme Q-10 does not improve liver function in people with hepatitis C who are not responding to conventional treatment.
  • High blood pressure. Some early research shows that taking coenzyme Q10 by itself or along with other medications for treating high blood pressure helps lowers blood pressure in people with high blood pressure. However, not all research has shown benefit. Coenzyme Q10 might only benefit people with high blood pressure who also have low blood levels of coenzyme Q10 before treatment.
  • A condition of an enlarged heart called hypertrophic cardiomyopathy. Taking coenzyme Q-10 by mouth seems to decrease the thickness of the heart wall and decrease symptoms of shortness of breath and fatigue in people with hypertrophic cardiomyopathy.
  • Male infertility. There is some early evidence that taking coenzyme Q10 or an altered form of coenzyme Q10 called ubiquinol by mouth can improve the movement and density of sperm in men with certain types of infertility. It appears that these benefits require at least 6 months of treatment. However, these improvements may not increase pregnancy rate.
  • Inherited diabetes and deafness. Early research suggests that taking coenzyme Q10 by mouth might prevent the progression of a rare form of diabetes that is maternally inherited.
  • Parkinson's disease. Some research shows that taking coenzyme Q10 might slow mental decline in people with early-stage Parkinson's disease. At least 16 months of treatment and doses above 600 mg daily appear to be needed to achieve these benefits. However, not all evidence has been positive. Other research suggests that coenzyme Q10 does not benefit people with early or mid-stage Parkinson's disease.
  • Gum disease. Applying coenzyme Q10 to the gums is not effective for treating gum disease. However, there is some early evidence that taking coenzyme Q10 by mouth might be helpful in treating gum disease.
  • Rare genetic disorder called Prader-Willi syndrome. Early research suggests that administering coenzyme Q10 improves mental and physical development in children with Prader-Labhart-Willi syndrome. However, it is not clear if these improvements are due to the coenzyme Q10 or an age-related phenomenon.
  • High blood pressure during pregnancy (pre-eclampsia). Pre-eclampsia is a condition that some women develop during pregnancy. Some research shows that women who are at risk have a lower chance of developing the condition if they take coenzyme Q10 from week 20 of pregnancy until the baby is delivered.
  • Prostate cancer. Research shows that taking a combination of vitamin E, selenium, vitamin C, and coenzyme Q10 does not improve biomarkers for prostate cancer.
  • Kidney failure. Some early research suggests that taking coenzyme Q10 improves kidney function in people with end-stage kidney disease. However, other research shows that taking coenzyme Q10 does not improve kidney function.
  • A muscle condition called "statin-induced myopathy." Statins, a class of drugs used to lower cholesterol, can sometimes cause muscle pain. There is some evidence that taking coenzyme Q10 might reduce this pain. However, not all evidence has been positive.
  • Hair loss related to use of the warfarin. There is some early evidence that taking coenzyme Q10 might be helpful for preventing hair loss caused by the blood-thinning drug, warfarin.
  • Wrinkled skin. Early evidence suggests that applying a coenzyme Q10 cream to the skin improves wrinkled skin.
  • Fatigue.
  • Lyme disease.
  • Other conditions.
More evidence is needed to rate coenzyme Q10 for these uses.

Side Effects

Side Effects & Safety

Coenzyme Q10 is LIKELY SAFE for most adults when taken by mouth or when applied directly to the gums. While most people tolerate coenzyme Q10 well, it can cause some mild side effects including stomach upset, loss of appetite, nausea, vomiting, and diarrhea. It can cause allergic skin rashes in some people. It also might lower blood pressure, so check your blood pressure carefully if you have very low blood pressure. Dividing the total daily dose by taking smaller amounts 2 or 3 times a day instead of a large amount all at once can help reduce side effects.

Coenzyme Q10 is POSSIBLY SAFE for children when taken by mouth. However, coenzyme Q-10 should not be used in children without medical supervision.

Special Precautions & Warnings:

Pregnancy and breast-feeding: Coenzyme Q10 is POSSIBLY SAFE when taken by mouth appropriately during pregnancy. Coenzyme Q10 has been used safely when taken twice daily starting at 20 weeks until delivery. Not enough is known about the use of coenzyme Q10 during breast-feeding. Stay on the safe side and avoid use.

Chemotherapy: People undergoing chemotherapy with a class of drugs called alkylating agents should use coenzyme Q10 with caution. There is some concern that coenzyme Q10 might lower the effectiveness of these drugs. Some alkylating agents include busulfan, carboplatin, cisplatin, cyclophosphamide (Cytoxan), dacarbazine, thiotepa, and many others.

High blood pressure or low blood pressure: Coenzyme Q10 might lower blood pressure. It can increase the effects of medications used to lower blood pressure. Discuss your use of coenzyme Q10 with your healthcare provider if you have blood pressure problems.

Smoking: Cigarette smoking depletes the amount of coenzyme Q10 stored by the body.

Surgery: Coenzyme Q10 might interfere with blood pressure control during and after surgery. Stop using coenzyme Q10 at least two weeks before a scheduled surgery.

Interactions

Interactions?

Moderate Interaction

Be cautious with this combination

!
  • Medications for cancer (Chemotherapy) interacts with COENZYME Q10

    Coenzyme Q-10 is an antioxidant. There is some concern that antioxidants might decrease the effectiveness of some medications used for cancers. But it is too soon to know if the interaction occurs.

  • Medications for high blood pressure (Antihypertensive drugs) interacts with COENZYME Q10

    Coenzyme Q-10 seems to decrease blood pressure. Taking coenzyme Q-10 along with medications for high blood pressure might cause your blood pressure to go too low.<br /><nb>Some medications for high blood pressure include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDiuril), furosemide (Lasix), and many others.

  • Warfarin (Coumadin) interacts with COENZYME Q10

    Warfarin (Coumadin) is used to slow blood clotting. Coenzyme Q-10 might help the blood clot. By helping the blood clot, coenzyme Q-10 might decrease the effectiveness of warfarin (Coumadin). Decreasing the effectiveness of warfarin (Coumadin) might increase the risk of clotting. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.

Dosing

Dosing

The following doses have been studied in scientific research:

ADULTS

BY MOUTH:

  • For coenzyme Q10 deficiency: 150-2400 mg per day.
  • For disorders that limit energy production in the cells of the body (mitochondrial disorders): 150-160 mg per day, or 2 mg/kg per day. In some cases, doses may be gradually increased to 3000 mg per day.
  • For age-related vision loss (age-related macular degeneration): A specific combination product containing 100 mg of acetyl-L-carnitine, 530 mg of omega-3 fatty acids, and 10 mg of coenzyme Q10 (Phototrop, Sigma-tau Health Science Ltd.) per day for one year.
  • For preventing death due to heart problems: A combination of 100 mg of coenzyme Q10 (Bio-Quinon, Pharma Nord) twice per day plus 200 mcg of selenium yeast (SelenoPrecise, Pharma Nord) per day for up to 5 years.
  • For heart failure: 100 mg per day divided into two or three doses for up to 4 months or 2 mg/kg daily for up to one year.
  • For nerve damage caused by diabetes (diabetic neuropathy): 400 mg per day for 12 weeks.
  • For fibromyalgia: 300 mg daily for about 6 weeks. Also 200 mg of coenzyme Q10 (Bio-Quinon Q10, Pharma Nord) plus 200 mg of ginkgo (Bio-Biloba, Pharma Nord) per day for 12 weeks.
  • For HIV/AIDS: 100-200 mg per day for over 4 years.
  • For blood vessel complications caused by heart bypass surgery: 150-300 mg per day in up to three divided doses for 1-2 weeks before surgery.
  • For a specific type of high blood pressure: 60 mg twice per day for 12 weeks.
  • For preventing migraine headache: 100 mg three times per day, 150 mg once per day, or 100mg once per day for 3 months. A dose of 1-3 mg/kg per day for 3 months has also been used.
  • For a muscle disorder called muscular dystrophy: 100 mg per day for 3 months.
  • For reducing the risk of future heart-related events in people with recent heart attack: 120 mg per day in two divided doses for up to one year. A combination of 100 mg of coenzyme Q10 (Bio-Quinon, Pharma Nord) and 100 mcg of selenium (Bio-Selenium, Pharma Nord) per day for up to one year has also been used.
  • For Peyronie's disease: 300 mg per day for 6 months.
CHILDREN

BY MOUTH:
  • For coenzyme Q10 deficiency: 60-250 mg per day in up to three divided doses.
  • For preventing migraine headache: 1-3 mg/kg daily for 3 months has been used in patients aged 3-18 years.
  • For a muscle disorder called muscular dystrophy: 100 mg daily for 3 months in children aged 8-15 years.

View References

REFERENCES:

  • Abe, K., Matsuo, Y., Kadekawa, J., Inoue, S., and Yanagihara, T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J Neurol.Sci. 1-1-1999;162(1):65-68. View abstract.
  • Ahn, J. H., Yoo, M. H., Lee, H. J., Chung, J. W., and Yoon, T. H. Coenzyme Q10 in combination with steroid therapy for treatment of sudden sensorineural hearing loss: a controlled prospective study. Clin Otolaryngol. 2010;35(6):486-489. View abstract.
  • Amadio E, Palermo R Peloni G Littarru G. Effect of CoQ10 administration on V02max and diastolic function in athletes. Biomedical and clinical aspects of Coenzyme Q10. 1991;525-533.
  • Aoki S and Yamaguchi K. [Clinical experiences in use of cinnarizine and CoQ10 for treatment of sensorineural tinnitus]. Shinyaku to Rinsho 1970;29:1541-1546.
  • Armstrong, M. J. and Miyasaki, J. M. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 8-7-2012;79(6):597-603. View abstract.
  • Artuch, R., Brea-Calvo, G., Briones, P., Aracil, A., Galvan, M., Espinos, C., Corral, J., Volpini, V., Ribes, A., Andreu, A. L., Palau, F., Sanchez-Alcazar, J. A., Navas, P., and Pineda, M. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol.Sci 7-15-2006;246(1-2):153-158. View abstract.
  • Aure, K., Benoist, J. F., Ogier, de Baulny, Romero, N. B., Rigal, O., and Lombes, A. Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology 8-24-2004;63(4):727-729. View abstract.
  • Azevedo, O., Vilarinho, L., Almeida, F., Ferreira, F., Guardado, J., Ferreira, M., Lourenco, A., Medeiros, R., and Almeida, J. Cardiomyopathy and kidney disease in a patient with maternally inherited diabetes and deafness caused by the 3243A>G mutation of mitochondrial DNA. Cardiology 2010;115(1):71-74. View abstract.
  • Baggio, E., Gandini, R., Plancher, A. C., Passeri, M., and Carmosino, G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure (interim analysis). The CoQ10 Drug Surveillance Investigators. Clin Investig. 1993;71(8 Suppl):S145-S149. View abstract.
  • Balercia G, Arnaldi G, Lucarelli G, and et al. Effects of exogenous CoQ10 administration in patients with idiopathic asthenozoospermia. International Journal of Andrology 2000;Suppl 23:43.
  • Balercia, G., Buldreghini, E., Vignini, A., Tiano, L., Paggi, F., Amoroso, S., Ricciardo-Lamonica, G., Boscaro, M., Lenzi, A., and Littarru, G. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil.Steril. 2009;91(5):1785-1792. View abstract.
  • Balercia, G., Mancini, A., Paggi, F., Tiano, L., Pontecorvi, A., Boscaro, M., Lenzi, A., and Littarru, G. P. Coenzyme Q10 and male infertility. J Endocrinol Invest 2009;32(7):626-632. View abstract.
  • Barbiroli, B., Frassineti, C., Martinelli, P., Iotti, S., Lodi, R., Cortelli, P., and Montagna, P. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol.Biol (Noisy.-le-grand) 1997;43(5):741-749. View abstract.
  • Barbiroli, B., Iotti, S., and Lodi, R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. Biofactors 1999;9(2-4):253-260. View abstract.
  • Barbiroli, B., Iotti, S., Cortelli, P., Martinelli, P., Lodi, R., Carelli, V., and Montagna, P. Low brain intracellular free magnesium in mitochondrial cytopathies. J Cereb.Blood Flow Metab 1999;19(5):528-532. View abstract.
  • Barboni, P., Valentino, M. L., La, Morgia C., Carbonelli, M., Savini, G., De, Negri A., Simonelli, F., Sadun, F., Caporali, L., Maresca, A., Liguori, R., Baruzzi, A., Zeviani, M., and Carelli, V. Idebenone treatment in patients with OPA1-mutant dominant optic atrophy. Brain 2013;136(Pt 2):e231. View abstract.
  • Barker, P. D. Reduced G tolerance associated with supplement use. Aviat.Space Environ.Med 2011;82(2):140-143. View abstract.
  • Beal, M. F. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism.Relat Disord. 2009;15 Suppl 3:S189-S194. View abstract.
  • Belaia, O. L., Kalmykova, V. I., Ivanova, L. A., and Kochergina, L. G. [Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia]. Klin Med (Mosk) 2006;84(5):59-62. View abstract.
  • Belcaro, G., Cesarone, M. R., Dugall, M., Hosoi, M., Ippolito, E., Bavera, P., and Grossi, M. G. Investigation of Pycnogenol(R) in combination with coenzymeQ10 in heart failure patients (NYHA II/III). Panminerva Med 2010;52(2 Suppl 1):21-25. View abstract.
  • Bentov, Y., Esfandiari, N., Burstein, E., and Casper, R. F. The use of mitochondrial nutrients to improve the outcome of infertility treatment in older patients. Fertil.Steril. 2010;93(1):272-275. View abstract.
  • Bergamin, C. S., Rolim, L. C., Dib, S. A., and Moises, R. S. Unusual occurrence of intestinal pseudo obstruction in a patient with maternally inherited diabetes and deafness (MIDD) and favorable outcome with coenzyme Q10. Arq Bras.Endocrinol Metabol. 2008;52(8):1345-1349. View abstract.
  • Berio, A. and Piazzi, A. Improvement of Kearns-Sayre syndrome with controlled carbohydrate intake and coenzyme Q10 therapy. Ophthalmologica 1994;208(6):342-343. View abstract.
  • Bessler, H., Bergman, M., Blumberger, N., Djaldetti, M., and Salman, H. Coenzyme Q10 decreases TNF-alpha and IL-2 secretion by human peripheral blood mononuclear cells. J Nutr Sci Vitaminol.(Tokyo) 2010;56(1):77-81. View abstract.
  • Beyer RE, Nordenbrand K, and Ernster L. The function of coenzyme Q in free radical production and as an antioxidant: a review. Chemica Scripta 1987;27:145-153.
  • Blatt, T., Mundt, C., Mummert, C., Maksiuk, T., Wolber, R., Keyhani, R., Schreiner, V., Hoppe, U., Schachtschabel, D. O., and Stab, F. [Modulation of oxidative stresses in human aging skin]. Z.Gerontol.Geriatr. 1999;32(2):83-88. View abstract.
  • Bloomer, R. J., Canale, R. E., McCarthy, C. G., and Farney, T. M. Impact of oral ubiquinol on blood oxidative stress and exercise performance. Oxid.Med.Cell Longev. 2012;2012:465020. View abstract.
  • Bolognesi, M. L., Matera, R., Minarini, A., Rosini, M., and Melchiorre, C. Alzheimer's disease: new approaches to drug discovery. Curr Opin.Chem Biol. 2009;13(3):303-308. View abstract.
  • Bookstaver, D. A., Burkhalter, N. A., and Hatzigeorgiou, C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am.J.Cardiol. 8-15-2012;110(4):526-529. View abstract.
  • Braun, B., Clarkson, P. M., Freedson, P. S., and Kohl, R. L. Effects of coenzyme Q10 supplementation on exercise performance, VO2max, and lipid peroxidation in trained cyclists. Int J Sport Nutr. 1991;1(4):353-365. View abstract.
  • Bresolin N, Cossutta E, Angelini C, and et al. Fifty patients with mitochondrial myopathy treated with ubidecarenone. First multicentric study. J Neurology 1988;235:S79.
  • Bresolin, N., Bet, L., Binda, A., Moggio, M., Comi, G., Nador, F., Ferrante, C., Carenzi, A., and Scarlato, G. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 1988;38(6):892-899. View abstract.
  • Bresolin, N., Bet, L., Ferrante, C., Binda, A., Carenzi, A., Moggio, M., Comi, G., and Scarlato, G. Immunological and biochemical studies and pilot therapeutic trial with ubidecarenone in Kearns-Sayre patients. Adv Neurol 1988;48:239-256. View abstract.
  • Brookman, R. H. and St Cyr, J. A. Metabolic supplementation with enhanced external counterpulsation improves myocardial function in acquired cardiomyopathy: a case report. J Altern.Complement Med 2010;16(3):323-325. View abstract.
  • Buyse, G. M., Goemans, N., van den Hauwe, M., Thijs, D., de Groot, I. J., Schara, U., Ceulemans, B., Meier, T., and Mertens, L. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. Neuromuscul.Disord. 2011;21(6):396-405. View abstract.
  • Cadoni, G., Scorpecci, A., Cianfrone, F., Giannantonio, S., Paludetti, G., and Lippa, S. Serum fatty acids and cardiovascular risk factors in sudden sensorineural hearing loss: a case-control study. Ann Otol.Rhinol.Laryngol. 2010;119(2):82-88. View abstract.
  • Caramia, G., Cocchi, M., Tonello, L., and Visci, G. [Childhood obesity: recent advances and an experimental contribution]. Pediatr Med Chir 2008;30(3):121-140. View abstract.
  • Celik, T. and Iyisoy, A. Coenzyme Q10 and coronary artery bypass surgery: what we have learned from clinical trials. J Cardiothorac.Vasc.Anesth. 2009;23(6):935-936. View abstract.
  • Centre for Reviews and Dissemination. Idebenone (SNT-MC17) for Friedreich's ataxia: horizon scanning technology briefing (Project record). 2013;
  • Chen, J. J. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment. Am J Manag.Care 2010;16 Suppl Implications:S87-S93. View abstract.
  • Chen, Y. F., Lin, Y. T., and Wu, S. C. Effectiveness of coenzyme Q10 on myocardial preservation during hypothermic cardioplegic arrest. J Thorac.Cardiovasc.Surg. 1994;107(1):242-247. View abstract.
  • Chew, G. T., Watts, G. F., Davis, T. M., Stuckey, B. G., Beilin, L. J., Thompson, P. L., Burke, V., and Currie, P. J. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 2008;31(8):1502-1509. View abstract.
  • Chinnery, P., Majamaa, K., Turnbull, D., and Thorburn, D. Treatment for mitochondrial disorders. Cochrane Database Syst.Rev. 2006;(1):CD004426. View abstract.
  • Chopra, R. K., Goldman, R., Sinatra, S. T., and Bhagavan, H. N. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam.Nutr Res 1998;68(2):109-113. View abstract.
  • Cicero, A. F., Derosa, G., Miconi, A., Laghi, L., Nascetti, S., and Gaddi, A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomed Pharmacother 2005;59(6):312-317. View abstract.
  • Cooney, R. V., Dai, Q., Gao, Y. T., Chow, W. H., Franke, A. A., Shu, X. O., Li, H., Ji, B., Cai, Q., Chai, W., and Zheng, W. Low plasma coenzyme Q(10) levels and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1124-1130. View abstract.
  • Cooper, J. M., Korlipara, L. V., Hart, P. E., Bradley, J. L., and Schapira, A. H. Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur.J Neurol. 2008;15(12):1371-1379. View abstract.
  • Cordero, M. D., Alcocer-Gomez, E., de, Miguel M., Cano-Garcia, F. J., Luque, C. M., Fernandez-Riejo, P., Fernandez, A. M., and Sanchez-Alcazar, J. A. Coenzyme Q(10): a novel therapeutic approach for Fibromyalgia? case series with 5 patients. Mitochondrion. 2011;11(4):623-625. View abstract.
  • Cordero, M. D., Cotan, D., del-Pozo-Martin, Y., Carrion, A. M., de, Miguel M., Bullon, P., and Sanchez-Alcazar, J. A. Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition 2012;28(11-12):1200-1203. View abstract.
  • Cordero, M. D., de, Miguel M., Moreno Fernandez, A. M., Carmona Lopez, I. M., Garrido, Maraver J., Cotan, D., Gomez, Izquierdo L., Bonal, P., Campa, F., Bullon, P., Navas, P., and Sanchez Alcazar, J. A. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 2010;12(1):R17. View abstract.
  • Cordero, M. D., Moreno-Fernandez, A. M., Carmona-Lopez, M. I., Sanchez-Alcazar, J. A., Rodriguez, A. F., Navas, P., and de, Miguel M. Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. Clin Biochem 2010;43(13-14):1174-1176. View abstract.
  • Cornelli, U. Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. Neurodegener.Dis 2010;7(1-3):193-202. View abstract.
  • Cortes, E. P., Gupta, M., Chou, C., Amin, V. C., and Folkers, K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat.Rep. 1978;62(6):887-891. View abstract.
  • Costeff, H., Apter, N., Elpeleg, O. N., Prialnic, M., and Bohles, H. J. Ineffectiveness of oral coenzyme Q10 supplementation in 3- methylglutaconic aciduria, type 3. Brain Dev. 1998;20(1):33-35. View abstract.
  • Cyrus-Hajmassy, M. [Bilateral visual deterioration in excessive tobacco and alcohol consumption]. Ophthalmologe 2012;109(9):901-906. View abstract.
  • D'Andrea, G., Bussone, G., Allais, G., Aguggia, M., D'Onofrio, F., Maggio, M., Moschiano, F., Saracco, M. G., Terzi, M. G., Petretta, V., and Benedetto, C. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol.Sci 2009;30 Suppl 1:S121-S124. View abstract.
  • Dai, Y. L., Luk, T. H., Yiu, K. H., Wang, M., Yip, P. M., Lee, S. W., Li, S. W., Tam, S., Fong, B., Lau, C. P., Siu, C. W., and Tse, H. F. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis 2011;216(2):395-401. View abstract.
  • Damian, M. S., Ellenberg, D., Gildemeister, R., Lauermann, J., Simonis, G., Sauter, W., and Georgi, C. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. Circulation 11-9-2004;110(19):3011-3016. View abstract.
  • Deichmann, R. E., Lavie, C. J., and Dornelles, A. C. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys.Sportsmed. 2012;40(4):88-95. View abstract.
  • Del Mar, C. B., Glasziou, P. P., Spinks, A. B., and Sanders, S. L. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 4-16-2001;174(8):421. View abstract.
  • Desnuelle, C., Pellissier, J. F., Serratrice, G., Pouget, J., and Turnbull, D. M. [Kearns-Sayre syndrome: mitochondrial encephalomyopathy caused by deficiency of the respiratory chain]. Rev Neurol (Paris) 1989;145(12):842-850. View abstract.
  • Digiesi V, Cantini F, and Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Current Therapeutic Research 1990;47(5):841-845.
  • Digiesi V, Cantini F, Bisi G, and et al. Mechanism of action of coenzyme Q10 in essential hypertension. Current Therapeutic Research 1992;51(5):668-672.
  • Disdier, P., Harle, J. R., Figarella-Branger, D., Cherif, A. A., Desnuelle, C., and Weiller, P. J. [Ptosis and asthenia manifesting a mitochondrial myopathy]. Rev Med Interne 1992;13(5):381-383. View abstract.
  • Donovan, L. E. and Severin, N. E. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J Clin Endocrinol.Metab 2006;91(12):4737-4742. View abstract.
  • Drinkard, B. E., Keyser, R. E., Paul, S. M., Arena, R., Plehn, J. F., Yanovski, J. A., and Di Prospero, N. A. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch Phys.Med Rehabil. 2010;91(7):1044-1050. View abstract.
  • Duncan, A. J., Bitner-Glindzicz, M., Meunier, B., Costello, H., Hargreaves, I. P., Lopez, L. C., Hirano, M., Quinzii, C. M., Sadowski, M. I., Hardy, J., Singleton, A., Clayton, P. T., and Rahman, S. A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet. 2009;84(5):558-566. View abstract.
  • Dunn, S. P., Bleske, B., Dorsch, M., Macaulay, T., Van, Tassell B., and Vardeny, O. Nutrition and heart failure: impact of drug therapies and management strategies. Nutr Clin Pract 2009;24(1):60-75. View abstract.
  • Eiholzer, U., Meinhardt, U., Rousson, V., Petrovic, N., Schlumpf, M., and l'Allemand, D. Developmental profiles in young children with Prader-Labhart-Willi syndrome: effects of weight and therapy with growth hormone or coenzyme Q10. Am J Med Genet.A 4-1-2008;146(7):873-880. View abstract.
  • El-ghoroury, E. A., Raslan, H. M., Badawy, E. A., El-Saaid, G. S., Agybi, M. H., Siam, I., and Salem, S. I. Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic control. Blood Coagul.Fibrinolysis 2009;20(4):248-251. View abstract.
  • Esposito, M. and Carotenuto, M. Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study. Neurol.Sci 9-25-2010; View abstract.
  • Esteves, A. R., Arduino, D. M., Swerdlow, R. H., Oliveira, C. R., and Cardoso, S. M. Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids. Antioxid.Redox.Signal. 2009;11(3):439-448. View abstract.
  • Feher, J., Kovacs, B., Kovacs, I., Schveoller, M., Papale, A., and Balacco, Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica 2005;219(3):154-166. View abstract.
  • Feigin A, Kieburtz K, Como P, and et al. An open-label trial of coenzyme Q10 (CoQ) in Huntington's disease (HD) [abstract]. Neurology 1994;44(suppl 2):A397-A398.
  • Ferrer, M. D., Tauler, P., Sureda, A., Pujol, P., Drobnic, F., Tur, J. A., and Pons, A. A soccer match's ability to enhance lymphocyte capability to produce ROS and induce oxidative damage. Int.J Sport Nutr Exerc.Metab 2009;19(3):243-258. View abstract.
  • Fetoni, A. R., Garzaro, M., Ralli, M., Landolfo, V., Sensini, M., Pecorari, G., Mordente, A., Paludetti, G., and Giordano, C. The monitoring role of otoacoustic emissions and oxidative stress markers in the protective effects of antioxidant administration in noise-exposed subjects: a pilot study. Med Sci Monit. 2009;15(11):R1-R8. View abstract.
  • Fiorella PL, Bargossi AM Grossi G Motta R Senaldi R Battino M Sassi S Sprovieri G Lubich T. Metabolic effects of coenzyme Q10 treatment in high level athletes. Biomedical and clinical aspects of Coenzyme Q10 1991;513-520.
  • Fogagnolo, P., Sacchi, M., Ceresara, G., Paderni, R., Lapadula, P., Orzalesi, N., and Rossetti, L. The effects of topical coenzyme Q10 and vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate after cataract surgery: a clinical and in vivo confocal study. Ophthalmologica 2013;229(1):26-31. View abstract.
  • Folkers K. Critique of coenzyme Q in biochemical and biomedical research and in ten years of clinical research on cardiovascular disease. J Mol Med 2002;2:431-460.
  • Folkers, K. and Wolaniuk, A. Research on coenzyme Q10 in clinical medicine and in immunomodulation. Drugs Exp.Clin Res 1985;11(8):539-545. View abstract.
  • Folkers, K., Drzewoski, J., Richardson, P. C., Ellis, J., Shizukuishi, S., and Baker, L. Bioenergetics in clinical medicine. XVI. Reduction of hypertension in patients by therapy with coenzyme Q10. Res Commun.Chem Pathol.Pharmacol 1981;31(1):129-140. View abstract.
  • Folkers, K., Langsjoen, P., and Langsjoen, P. H. Therapy with coenzyme Q10 of patients in heart failure who are eligible or ineligible for a transplant. Biochem Biophys.Res Commun. 1-15-1992;182(1):247-253. View abstract.
  • Folkers, K., Morita, M., and McRee, J., Jr. The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochem Biophys.Res Commun. 5-28-1993;193(1):88-92. View abstract.
  • Folkers, K., Wolaniuk, J., Simonsen, R., Morishita, M., and Vadhanavikit, S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc.Natl.Acad.Sci U.S.A 1985;82(13):4513-4516. View abstract.
  • Forgionne, G. A. Bovine cartilage, coenzyme Q10, and wheat grass therapy for primary peritoneal cancer. J Altern.Complement Med 2005;11(1):161-165. View abstract.
  • Fujimoto, S., Kurihara, N., Hirata, K., and Takeda, T. Effects of coenzyme Q10 administration on pulmonary function and exercise performance in patients with chronic lung diseases. Clin Investig. 1993;71(8 Suppl):S162-S166. View abstract.
  • Fumagalli, S., Fattirolli, F., Guarducci, L., Cellai, T., Baldasseroni, S., Tarantini, F., Di, Bari M., Masotti, G., and Marchionni, N. Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol. 2011;34(4):211-217. View abstract.
  • Galili, N., Sechman, E. V., Cerny, J., Mehdi, M., Mumtaz, M., Westervelt, P., Maguire, J., and Raza, A. Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10. Leuk.Res 2007;31(1):19-26. View abstract.
  • Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A., and Murphy, M. P. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019-1026. View abstract.
  • Gazdikova, K., Gvozdjakova, A., Kucharska, J., Spustova, V., Braunova, Z., and Dzurik, R. [Effect of coenzyme Q10 in patients with kidney diseases]. Cas.Lek.Cesk. 5-24-2001;140(10):307-310. View abstract.
  • Geng, A., Li, B., and Guo, Y. Effects of dietary L-carnitine and coenzyme Q10 at different supplemental ages on growth performance and some immune response in ascites-susceptible broilers. Arch.Anim Nutr. 2007;61(1):50-60. View abstract.
  • Gerards, M., van den Bosch, B., Calis, C., Schoonderwoerd, K., van, Engelen K., Tijssen, M., de, Coo R., van der Kooi, A., and Smeets, H. Nonsense mutations in CABC1/ADCK3 cause progressive cerebellar ataxia and atrophy. Mitochondrion. 2010;10(5):510-515. View abstract.
  • Ghiringhelli, G. [Therapy with ubidecarenone in various cardiopathies with and without decompensation. Comparison with a standard therapy]. Boll.Chim.Farm. 1986;125(3):28S-33S. View abstract.
  • Gini, M., Schiavi, M., and Mazzola, C. [Ubidecarenone (coenzyme Q10) in the therapy of chronic cor pulmonale]. Boll.Chim.Farm. 1985;124(4):21S-28S. View abstract.
  • Glover, E. I., Martin, J., Maher, A., Thornhill, R. E., Moran, G. R., and Tarnopolsky, M. A. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010;42(5):739-748. View abstract.
  • Goda, S., Hamada, T., Ishimoto, S., Kobayashi, T., Goto, I., and Kuroiwa, Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol. 1987;234(1):62-63. View abstract.
  • Gokbel, H., Gul, I., Belviranl, M., and Okudan, N. The effects of coenzyme Q10 supplementation on performance during repeated bouts of supramaximal exercise in sedentary men. J Strength Cond.Res 2010;24(1):97-102. View abstract.
  • Gold, R., Seibel, P., Reinelt, G., Schindler, R., Landwehr, P., Beck, A., and Reichmann, H. Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. Eur.Neurol. 1996;36(4):191-196. View abstract.
  • Golomb, B. A., Kwon, E. K., Koperski, S., and Evans, M. A. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf 2009;32(8):649-661. View abstract.
  • Gottlieb, S. S., Khatta, M., and Fisher, M. L. Coenzyme Q10 and Congestive Heart Failure. Ann.Intern.Med 11-7-2000;133(9):745-746. View abstract.
  • Gregersen, N., Andresen, B. S., Pedersen, C. B., Olsen, R. K., Corydon, T. J., and Bross, P. Mitochondrial fatty acid oxidation defects--remaining challenges. J Inherit.Metab Dis 2008;31(5):643-657. View abstract.
  • Gruber, J., Schaffer, S., and Halliwell, B. The mitochondrial free radical theory of ageing--where do we stand? Front Biosci 2008;13:6554-6579. View abstract.
  • Guastini, L., Mora, R., Dellepiane, M., Santomauro, V., Giorgio, M., and Salami, A. Water-soluble coenzyme Q10 formulation in presbycusis: long-term effects. Acta Otolaryngol. 2011;131(5):512-517. View abstract.
  • Gul, I., Gokbel, H., Belviranli, M., Okudan, N., Buyukbas, S., and Basarali, K. Oxidative stress and antioxidant defense in plasma after repeated bouts of supramaximal exercise: the effect of coenzyme Q10. J Sports Med Phys.Fitness 2011;51(2):305-312. View abstract.
  • Gutzmann, H., Kuhl, K. P., Hadler, D., and Rapp, M. A. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002;35(1):12-18. View abstract.
  • Gvozdjakova A, Kucharska J, Braunova Z, and et al. Beneficial effect of CoQ10 on the antioxidative status and metabolism of fats and sugars in diabetic patients. First Conference of the International Coenzyme Q10 Association 2002;
  • Gvozdjakova A, Kucharska J, Lepies P, and et al. Decreased level of sperm coenzyme Q10, mitochondrial respiration and energy production in infertile patients therapeutic effect on coenzyme Q10 (a pilot study). First Conference of the International Coenzyme Q10 Association 2002;
  • Gvozdjakova, A., Kucharska, J., Bartkovjakova, M., Gazdikova, K., and Gazdik, F. E. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 2005;25(1-4):235-240. View abstract.
  • Haginoya, K., Miyabayashi, S., Kikuchi, M., Kojima, A., Yamamoto, K., Omura, K., Uematsu, M., Hino-Fukuyo, N., Tanaka, S., and Tsuchiya, S. Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study. J Neurol.Sci 3-15-2009;278(1-2):112-114. View abstract.
  • Hamilton, S. J., Chew, G. T., and Watts, G. F. Coenzyme Q10 improves endothelial dysfunction in statin-treated type 2 diabetic patients. Diabetes Care 2009;32(5):810-812. View abstract.
  • Hanisch, F. and Zierz, S. Only transient increase of serum CoQ subset 10 during long-term CoQ10 therapy in mitochondrial ophthalmoplegia. Eur.J Med.Res 11-12-2003;8(11):485-491. View abstract.
  • Harinstein, M. E., Berliner, J. I., Shah, S. J., Taegtmeyer, H., and Gheorghiade, M. Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observations in 11 patients. Am J Ther 2008;15(3):206-213. View abstract.
  • Hart, P. E., Lodi, R., Rajagopalan, B., Bradley, J. L., Crilley, J. G., Turner, C., Blamire, A. M., Manners, D., Styles, P., Schapira, A. H., and Cooper, J. M. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch.Neurol. 2005;62(4):621-626. View abstract.
  • Hauser, R. A. Early pharmacologic treatment in Parkinson's disease. Am J Manag.Care 2010;16 Suppl Implications:S100-S107. View abstract.
  • Henchcliffe, C. and Beal, M. F. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat.Clin Pract Neurol. 2008;4(11):600-609. View abstract.
  • Hernandez-Ojeda, J., Cardona-Munoz, E. G., Roman-Pintos, L. M., Troyo-Sanroman, R., Ortiz-Lazareno, P. C., Cardenas-Meza, M. A., Pascoe-Gonzalez, S., and Miranda-Diaz, A. G. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J.Diabetes Complications 2012;26(4):352-358. View abstract.
  • Hertz, N. and Lister, R. E. Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study. J Int.Med Res 2009;37(6):1961-1971. View abstract.
  • Hidaka, T., Fujii, K., Funahashi, I., Fukutomi, N., and Hosoe, K. Safety assessment of coenzyme Q10 (CoQ10). Biofactors 2008;32(1-4):199-208. View abstract.
  • Hirano, M., Quinzii, C. M., and DiMauro, S. Restoring balance to ataxia with coenzyme Q10 deficiency. J Neurol.Sci 7-15-2006;246(1-2):11-12. View abstract.
  • Hoenjet, K. M., Dagnelie, P. C., Delaere, K. P., Wijckmans, N. E., Zambon, J. V., and Oosterhof, G. O. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study. Eur Urol 2005;47(4):433-439. View abstract.
  • Horvath, R., Gorman, G., and Chinnery, P. F. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics. 2008;5(4):558-568. View abstract.
  • Horvath, R., Schneiderat, P., Schoser, B. G., Gempel, K., Neuen-Jacob, E., Ploger, H., Muller-Hocker, J., Pongratz, D. E., Naini, A., DiMauro, S., and Lochmuller, H. Coenzyme Q10 deficiency and isolated myopathy. Neurology 1-24-2006;66(2):253-255. View abstract.
  • Iarussi, D., Auricchio, U., Agretto, A., Murano, A., Giuliano, M., Casale, F., Indolfi, P., and Iacono, A. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non- Hodgkin lymphoma. Mol.Aspects Med 1994;15 Suppl:s207-s212. View abstract.
  • Imanaka K, Izumiyama K, and Sakaguchi T et al. Effect of coenzyme Q10 and azelastin on protecting radiation pneumonitis with lung cancer. Journal of Japan Society for Cancer Therapy 1994;29:2010-2015.
  • Inui, M., Ooe, M., Fujii, K., Matsunaka, H., Yoshida, M., and Ichihashi, M. Mechanisms of inhibitory effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. Biofactors 2008;32(1-4):237-243. View abstract.
  • Ishiyama, T., Morita, Y., Toyama, S., Yamagami, T., and Tsukamoto, N. A clinical study of the effect of coenzyme Q on congestive heart failure. Jpn.Heart J 1976;17(1):32-42. View abstract.
  • Islam, J., Uretsky, B. F., and Sierpina, V. S. Heart failure improvement with CoQ10, Hawthorn, and magnesium in a patient scheduled for cardiac resynchronization-defibrillator therapy: a case study. Explore.(NY) 2006;2(4):339-341. View abstract.
  • Isobe, C., Abe, T., and Terayama, Y. Increase in the oxidized/total coenzyme Q-10 ratio in the cerebrospinal fluid of Alzheimer's disease patients. Dement.Geriatr.Cogn Disord. 2009;28(5):449-454. View abstract.
  • Isobe, C., Abe, T., and Terayama, Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci.Lett. 1-18-2010;469(1):159-163. View abstract.
  • Isobe, C., Abe, T., and Terayama, Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J Neurol. 2010;257(3):399-404. View abstract.
  • Jacobson, B. H., Smith, D. B., Warren, A. J., Glass, R. G., Kline, C., Fedick, J. L., and Stemm, J. Assessment of the effectiveness of a sublingual, ergogenic spray on muscle strength and power. J Strength Cond.Res 2009;23(8):2326-2330. View abstract.
  • Jeejeebhoy, F., Keith, M., Freeman, M., Barr, A., McCall, M., Kurian, R., Mazer, D., and Errett, L. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 2002;143(6):1092-1100. View abstract.
  • Jimenez-Caballero, P. E., Mollejo-Villanueva, M., and Alvarez-Tejerina, A. [Mitochondrial encephalopathy due to complex I deficiency. Brain tissue biopsy findings and clinical course following pharmacological]. Rev.Neurol. 7-1-2008;47(1):27-30. View abstract.
  • Judy WV, Folkers K, and Hall JH. Improved long-term survival in conezyme Q10 treated chronic heart failure patients compared to conventionally treated patients. In: Folkers K, Littarru GP, and Yamagami T. Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier Science Publishers;1991.
  • Judy WV, Willis RA, and Folkers K. Regression of prostate cancer and plasma specific antigens (PSA) in patients on treatment with COQ10. First Conference of the International Coenzyme Q10 Association 2002;
  • Judy, W. V., Hall, J. H., Toth, P. D., and Folkers, K. Double blind double cross over study of coenzyme Q10 in heart failure. In: Folkers, K. and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1986.
  • Judy, W. V., Stogsdill, W. W., and Folkers, K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin Investig. 1993;71(8 Suppl):S155-S161. View abstract.
  • Kaikkonen, J., Kosonen, L., Nyyssonen, K., Porkkala-Sarataho, E., Salonen, R., Korpela, H., and Salonen, J. T. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic.Res 1998;29(1):85-92. View abstract.
  • Kaji, S., Murayama, K., Nagata, I., Nagasaka, H., Takayanagi, M., Ohtake, A., Iwasa, H., Nishiyama, M., Okazaki, Y., Harashima, H., Eitoku, T., Yamamoto, M., Matsushita, H., Kitamoto, K., Sakata, S., Katayama, T., Sugimoto, S., Fujimoto, Y., Murakami, J., Kanzaki, S., and Shiraki, K. Fluctuating liver functions in siblings with MPV17 mutations and possible improvement associated with dietary and pharmaceutical treatments targeting respiratory chain complex II. Mol.Genet.Metab 2009;97(4):292-296. View abstract.
  • Kang, H. C., Kim, H. D., Lee, Y. M., and Han, S. H. Landau-Kleffner syndrome with mitochondrial respiratory chain-complex I deficiency. Pediatr.Neurol. 2006;35(2):158-161. View abstract.
  • Kato, T., Yoneda, S., Kako, T., Koketsu, M., Hayano, I., and Fujinami, T. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease. Int J Clin Pharmacol Ther.Toxicol 1990;28(3):123-126. View abstract.
  • Kaufmann, P., Thompson, J. L., Levy, G., Buchsbaum, R., Shefner, J., Krivickas, L. S., Katz, J., Rollins, Y., Barohn, R. J., Jackson, C. E., Tiryaki, E., Lomen-Hoerth, C., Armon, C., Tandan, R., Rudnicki, S. A., Rezania, K., Sufit, R., Pestronk, A., Novella, S. P., Heiman-Patterson, T., Kasarskis, E. J., Pioro, E. P., Montes, J., Arbing, R., Vecchio, D., Barsdorf, A., Mitsumoto, H., and Levin, B. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66(2):235-244. View abstract.
  • Kearney, M., Orrell, R. W., Fahey, M., and Pandolfo, M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst.Rev. 2009;(4):CD007791. View abstract.
  • Kearney, M., Orrell, R. W., Fahey, M., and Pandolfo, M. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst.Rev. 2012;4:CD007791. View abstract.
  • Keith, M., Mazer, C. D., Mikhail, P., Jeejeebhoy, F., Briet, F., and Errett, L. Coenzyme Q10 in patients undergoing CABG: Effect of statins and nutritional supplementation. Nutr Metab Cardiovasc.Dis. 2008;18(2):105-111. View abstract.
  • Kelly P, Vasu S Getato M McNurlan M Lawson WE. Coenzyme Q10 improves myopathic pain in statin treated patients (abstr). J Am Coll Cardiol 2005;45:3A.
  • Kernt, M., Hirneiss, C., Neubauer, A. S., Ulbig, M. W., and Kampik, A. Coenzyme Q10 prevents human lens epithelial cells from light-induced apoptotic cell death by reducing oxidative stress and stabilizing BAX / Bcl-2 ratio. Acta Ophthalmol. 2010;88(3):e78-e86. View abstract.
  • Kerr, D. S. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol.Genet.Metab 2010;99(3):246-255. View abstract.
  • Khan, M., Gross, J., Haupt, H., Jainz, A., Niklowitz, P., Scherer, H., Schmidt, F. P., Klapp, B. F., Reisshauer, A., and Mazurek, B. A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium. Otolaryngol.Head Neck Surg 2007;136(1):72-77. View abstract.
  • Kharaeva, Z., Gostova, E., de, Luca C., Raskovic, D., and Korkina, L. Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. Nutrition 2009;25(3):295-302. View abstract.
  • Kim, Y., Sawada, Y., Fujiwara, G., Chiba, H., and Nishimura, T. Therapeutic effect of co-enzyme Q10 on idiopathic dilated cardiomyopathy: assessment by iodine-123 labelled 15-(p-iodophenyl)- 3(R,S)-methylpentadecanoic acid myocardial single-photon emission tomography. Eur.J Nucl.Med 1997;24(6):629-634. View abstract.
  • Klopstock, T., Metz, G., Yu-Wai-Man, P., Buchner, B., Gallenmuller, C., Bailie, M., Nwali, N., Griffiths, P. G., von, Livonius B., Reznicek, L., Rouleau, J., Coppard, N., Meier, T., and Chinnery, P. F. Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy. Brain 2013;136(Pt 2):e230. View abstract.
  • Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., Kernt, M., Petraki, D., Rummey, C., Leinonen, M., Metz, G., Griffiths, P. G., Meier, T., and Chinnery, P. F. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain 2011;134(Pt 9):2677-2686. View abstract.
  • Kocharian, A., Shabanian, R., Rafiei-Khorgami, M., Kiani, A., and Heidari-Bateni, G. Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy. Cardiol.Young. 2009;19(5):501-506. View abstract.
  • Kogan, A. K., Syrkin, A. L., Drinitsina, S. V., and Kokanova, I. V. [The antioxidant protection of the heart by coenzyme Q10 in stable stenocardia of effort]. Patol.Fiziol.Eksp.Ter. 1999;4(4):16-19. View abstract.
  • Kon, M., Tanabe, K., Akimoto, T., Kimura, F., Tanimura, Y., Shimizu, K., Okamoto, T., and Kono, I. Reducing exercise-induced muscular injury in kendo athletes with supplementation of coenzyme Q10. Br J Nutr 2008;100(4):903-909. View abstract.
  • Koroshetz WJ. Care-HD: NINDS multicenter trial in Huntington's disease to test whether specific doses of coenzyme Q10 and remacemide slow disease progression. First Conference of the International Coenzyme Q10 Association 2002;
  • Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., and Beal, M. F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann.Neurol. 1997;41(2):160-165. View abstract.
  • Kuklinski, B., Weissenbacher, E., and Fahnrich, A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol.Aspects Med 1994;15 Suppl:s143-s147. View abstract.
  • Laaksonen, R., Fogelholm, M., Himberg, J. J., Laakso, J., and Salorinne, Y. Ubiquinone supplementation and exercise capacity in trained young and older men. Eur.J Appl.Physiol Occup.Physiol 1995;72(1-2):95-100. View abstract.
  • Lagedrost, S. J., Sutton, M. S., Cohen, M. S., Satou, G. M., Kaufman, B. D., Perlman, S. L., Rummey, C., Meier, T., and Lynch, D. R. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J 2011;161(3):639-645. View abstract.
  • Lagendijk, J., Ubbink, J. B., Delport, R., Vermaak, W. J., and Human, J. A. Ubiquinol/ubiquinone ratio as marker of oxidative stress in coronary artery disease. Res Commun.Mol Pathol.Pharmacol. 1997;95(1):11-20. View abstract.
  • Laguna, T. A., Sontag, M. K., Osberg, I., Wagener, J. S., Accurso, F. J., and Sokol, R. J. Decreased total serum coenzyme-Q10 concentrations: a longitudinal study in children with cystic fibrosis. J Pediatr 2008;153(3):402-407. View abstract.
  • Langsjoen PH. Treatment of patients with human immunodeficiency virus infection with coenzyme Q10. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1991.
  • Langsjoen, H., Langsjoen, P., Langsjoen, P., Willis, R., and Folkers, K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Mol.Aspects Med 1994;15 Suppl:s165-s175. View abstract.
  • Langsjoen, P. H. and Langsjoen, A. M. Overview of the use of CoQ10 in cardiovascular disease. Biofactors 1999;9(2-4):273-284. View abstract.
  • Langsjoen, P. H. and Langsjoen, A. M. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. View abstract.
  • Langsjoen, P. H., Folkers, K., Lyson, K., Muratsu, K., Lyson, T., and Langsjoen, P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr 7-1-1988;66(13):583-590. View abstract.
  • Langsjoen, P. H., Folkers, K., Lyson, K., Muratsu, K., Lyson, T., and Langsjoen, P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React. 1990;12(3):163-168. View abstract.
  • Langsjoen, P. H., Langsjoen, P. H., and Folkers, K. A six-year clinical study of therapy of cardiomyopathy with coenzyme Q10. Int J Tissue React. 1990;12(3):169-171. View abstract.
  • Langsjoen, P. H., Langsjoen, P. H., and Folkers, K. Isolated diastolic dysfunction of the myocardium and its response to CoQ10 treatment. Clin Investig. 1993;71(8 Suppl):S140-S144. View abstract.
  • Langsjoen, P. H., Vadhanavikit, S., and Folkers, K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc.Natl.Acad.Sci U.S.A 1985;82(12):4240-4244. View abstract.
  • Larijani, V. N., Ahmadi, N., Zeb, I., Khan, F., Flores, F., and Budoff, M. Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function: the FAITH randomized clinical trial. Nutrition 2013;29(1):71-75. View abstract.
  • Lee, B. J., Huang, Y. C., Chen, S. J., and Lin, P. T. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with coronary artery disease. Nutrition 2012;28(3):250-255. View abstract.
  • Lee, B. J., Huang, Y. C., Chen, S. J., and Lin, P. T. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 2012;28(7-8):767-772. View abstract.
  • Lee, D. S., Badr, M. S., and Mateika, J. H. Progressive augmentation and ventilatory long-term facilitation are enhanced in sleep apnoea patients and are mitigated by antioxidant administration. J Physiol 11-15-2009;587(Pt 22):5451-5467. View abstract.
  • Lee, T. I., Kao, Y. H., Chen, Y. C., and Chen, Y. J. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors. Eur.J Clin Invest 2009;39(1):23-30. View abstract.
  • Lekoubou, A., Kouame-Assouan, A. E., Cho, T. H., Luaute, J., Nighoghossian, N., and Derex, L. Effect of long-term oral treatment with L-arginine and idebenone on the prevention of stroke-like episodes in an adult MELAS patient. Rev.Neurol.(Paris) 2011;167(11):852-855. View abstract.
  • Letsas, K. P., Efremidis, M., Pappas, L. K., Gavrielatos, G., Sideris, A., and Charitos, C. Pathophysiology and management of syncope in Kearns-Sayre syndrome. Am Heart Hosp.J 2006;4(4):301-302. View abstract.
  • Levy, G., Kaufmann, P., Buchsbaum, R., Montes, J., Barsdorf, A., Arbing, R., Battista, V., Zhou, X., Mitsumoto, H., Levin, B., and Thompson, J. L. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 3-14-2006;66(5):660-663. View abstract.
  • LeWitt, P. A. and Taylor, D. C. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics. 2008;5(2):210-225. View abstract.
  • Littarru, G. P., Nakamura, R., Ho, L., Folkers, K., and Kuzell, W. C. Deficiency of coenzyme Q 10 in gingival tissue from patients with periodontal disease. Proc.Natl.Acad.Sci U.S.A 1971;68(10):2332-2335. View abstract.
  • Liu, J., Wang, L., Zhan, S. Y., and Xia, Y. Coenzyme Q10 for Parkinson's disease. Cochrane Database Syst.Rev. 2011;(12):CD008150. View abstract.
  • Liu, Z. X. and Artmann, C. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Altern.Ther Health Med 2009;15(2):42-46. View abstract.
  • Lockwood, K., Moesgaard, S., Hanioka, T., and Folkers, K. Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol.Aspects Med 1994;15 Suppl:s231-s240. View abstract.
  • Lodi, R., Hart, P. E., Rajagopalan, B., Taylor, D. J., Crilley, J. G., Bradley, J. L., Blamire, A. M., Manners, D., Styles, P., Schapira, A. H., and Cooper, J. M. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann.Neurol. 2001;49(5):590-596. View abstract.
  • Lopez, L. C., Schuelke, M., Quinzii, C. M., Kanki, T., Rodenburg, R. J., Naini, A., DiMauro, S., and Hirano, M. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum.Genet. 2006;79(6):1125-1129. View abstract.
  • Lynch, D. R., Perlman, S. L., and Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67(8):941-947. View abstract.
  • Maeda, K., Tatsumi, M., Tahara, M., Murata, Y., Kawai, H., and Yasuda, H. [A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone]. Rinsho Shinkeigaku 2005;45(6):416-421. View abstract.
  • Makhija, N., Sendasgupta, C., Kiran, U., Lakshmy, R., Hote, M. P., Choudhary, S. K., Airan, B., and Abraham, R. The role of oral coenzyme Q10 in patients undergoing coronary artery bypass graft surgery. J Cardiothorac.Vasc.Anesth. 2008;22(6):832-839. View abstract.
  • Malm, C., Svensson, M., Sjoberg, B., Ekblom, B., and Sjodin, B. Supplementation with ubiquinone-10 causes cellular damage during intense exercise. Acta Physiol Scand. 1996;157(4):511-512. View abstract.
  • Manzoli, U., Rossi, E., Littarru, G. P., Frustaci, A., Lippa, S., Oradei, A., and Aureli, V. Coenzyme Q10 in dilated cardiomyopathy. Int J Tissue React. 1990;12(3):173-178. View abstract.
  • Marazzi, G., Cacciotti, L., Pelliccia, F., Iaia, L., Volterrani, M., Caminiti, G., Sposato, B., Massaro, R., Grieco, F., and Rosano, G. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv.Ther 2011;28(12):1105-1113. View abstract.
  • Mari D, Alleva R, Tomasetti M, and et al. Reduction of chemotoxicity and enhancement of antioxidant capacity of plasma in cancer patients treated with conventional therapy plus CoQ10. First Conference of the International Coenzyme Q10 Association 2002;
  • Matsumura, T., Saji, S., Nakamura, R., and Folkers, K. Evidence for enhanced treatment of periodontal disease by therapy with coenzyme Q. Int J Vitam.Nutr Res 1973;43(4):537-548. View abstract.
  • Matthews, P. M., Ford, B., Dandurand, R. J., Eidelman, D. H., O'Connor, D., Sherwin, A., Karpati, G., Andermann, F., and Arnold, D. L. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43(5):884-890. View abstract.
  • Mauskop, A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap.Minn.) 2012;18(4):796-806. View abstract.
  • Mazzola C, Guffanti EE, Vaccarella A, and et al. Noninvasive assessment of coenzyme Q10 in patients with chronic stable effort angina and moderate heart failure. Current Therapeutic Research 1987;41(6):923-932.
  • Meier, T. and Buyse, G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol. 2009;256 Suppl 1:25-30. View abstract.
  • Meier, T., Perlman, S. L., Rummey, C., Coppard, N. J., and Lynch, D. R. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012;259(2):284-291. View abstract.
  • Menke, T., Niklowitz, P., Wiesel, T., and Andler, W. Antioxidant level and redox status of coenzyme Q10 in the plasma and blood cells of children with diabetes mellitus type 1. Pediatr Diabetes 2008;9(6):540-545. View abstract.
  • Mestre, T., Ferreira, J., Coelho, M. M., Rosa, M., and Sampaio, C. Therapeutic interventions for disease progression in Huntington's disease. Cochrane.Database.Syst.Rev. 2009;(3):CD006455. View abstract.
  • Mikhin, V. P., Kharchenko, A. V., Rosliakova, E. A., and Cherniatina, M. A. [Application of coenzyme Q(10) in combination therapy of arterial hypertension]. Kardiologiia. 2011;51(6):26-31. View abstract.
  • Miles, M. V., Tang, P. H., Miles, L., Steele, P. E., Moye, M. J., and Horn, P. S. Validation and application of an HPLC-EC method for analysis of coenzyme Q10 in blood platelets. Biomed.Chromatogr. 2008;22(12):1403-1408. View abstract.
  • Mischley, L. K., Allen, J., and Bradley, R. Coenzyme Q10 deficiency in patients with Parkinson's disease. J.Neurol.Sci. 7-15-2012;318(1-2):72-75. View abstract.
  • Mizuno, K., Tanaka, M., Nozaki, S., Mizuma, H., Ataka, S., Tahara, T., Sugino, T., Shirai, T., Kajimoto, Y., Kuratsune, H., Kajimoto, O., and Watanabe, Y. Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition 2008;24(4):293-299. View abstract.
  • Mizuno, M., Quistorff, B., Theorell, H., Theorell, M., and Chance, B. Effects of oral supplementation of coenzyme Q10 on 31P-NMR detected skeletal muscle energy metabolism in middle-aged post-polio subjects and normal volunteers. Mol.Aspects Med 1997;18 Suppl:S291-S298. View abstract.
  • Mizushina, Y., Takeuchi, T., Takakusagi, Y., Yonezawa, Y., Mizuno, T., Yanagi, K., Imamoto, N., Sugawara, F., Sakaguchi, K., Yoshida, H., and Fujita, M. Coenzyme Q10 as a potent compound that inhibits Cdt1-geminin interaction. Biochim.Biophys.Acta 2008;1780(2):203-213. View abstract.
  • Mohr, D., Bowry, V. W., and Stocker, R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 6-26-1992;1126(3):247-254. View abstract.
  • Molyneux, S. L., Florkowski, C. M., George, P. M., Pilbrow, A. P., Frampton, C. M., Lever, M., and Richards, A. M. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll.Cardiol. 10-28-2008;52(18):1435-1441. View abstract.
  • Molyneux, S. L., Florkowski, C. M., Richards, A. M., Lever, M., Young, J. M., and George, P. M. Coenzyme Q10; an adjunctive therapy for congestive heart failure? N.Z.Med J 10-30-2009;122(1305):74-79. View abstract.
  • Montero, R., Sanchez-Alcazar, J. A., Briones, P., Navarro-Sastre, A., Gallardo, E., Bornstein, B., Herrero-Martin, D., Rivera, H., Martin, M. A., Marti, R., Garcia-Cazorla, A., Montoya, J., Navas, P., and Artuch, R. Coenzyme Q10 deficiency associated with a mitochondrial DNA depletion syndrome: a case report. Clin Biochem. 2009;42(7-8):742-745. View abstract.
  • Montini, G., Malaventura, C., and Salviati, L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N.Engl.J Med 6-26-2008;358(26):2849-2850. View abstract.
  • Mori, T. A., Burke, V., Puddey, I., Irish, A., Cowpland, C. A., Beilin, L., Dogra, G., and Watts, G. F. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens. 2009;27(9):1863-1872. View abstract.
  • Morre, D. J. and Morre, D. M. arNOX activity of saliva as a non-invasive measure of coenzyme Q10 response in human trials. Biofactors 2008;32(1-4):231-235. View abstract.
  • Morre, D. M., Morre, D. J., Rehmus, W., and Kern, D. Supplementation with CoQ10 lowers age-related (ar) NOX levels in healthy subjects. Biofactors 2008;32(1-4):221-230. View abstract.
  • Mortensen, S. A., Vadhanavikit, S., Baandrup, U., and Folkers, K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure. Drugs Exp.Clin Res 1985;11(8):581-593. View abstract.
  • Muller, T., Buttner, T., Gholipour, A. F., and Kuhn, W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci.Lett. 5-8-2003;341(3):201-204. View abstract.
  • Muller-Steinwachs, J, Anda, LP, and Zilliken, F. Eine klinische Doppel-blind-studie mit CoQ10 und vitamin E bei hertzkranken patienten. De Orthomoleculaire Koerier 1990;5(24):4-11.
  • Murata, T., Ohtsuka, C., and Terayama, Y. Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis. Free Radic.Res 2008;42(3):221-225. View abstract.
  • Murata, T., Ohtsuka, C., and Terayama, Y. Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol.Sci 4-15-2008;267(1-2):66-69. View abstract.
  • Muta-Takada, K., Terada, T., Yamanishi, H., Ashida, Y., Inomata, S., Nishiyama, T., and Amano, S. Coenzyme Q10 protects against oxidative stress-induced cell death and enhances the synthesis of basement membrane components in dermal and epidermal cells. Biofactors 2009;35(5):435-441. View abstract.
  • Myers, L., Farmer, J. M., Wilson, R. B., Friedman, L., Tsou, A., Perlman, S. L., Subramony, S. H., Gomez, C. M., Ashizawa, T., Wilmot, G. R., Mathews, K. D., Balcer, L. J., and Lynch, D. R. Antioxidant use in Friedreich ataxia. J Neurol.Sci 4-15-2008;267(1-2):174-176. View abstract.
  • Nadjarzadeh, A., Sadeghi, M. R., Amirjannati, N., Vafa, M. R., Motevalian, S. A., Gohari, M. R., Akhondi, M. A., Yavari, P., and Shidfar, F. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. J Endocrinol.Invest 2011;34(8):e224-e228. View abstract.
  • Nahas, R. Complementary and alternative medicine approaches to blood pressure reduction: An evidence-based review. Can.Fam.Physician 2008;54(11):1529-1533. View abstract.
  • Nielsen, A. N., Mizuno, M., Ratkevicius, A., Mohr, T., Rohde, M., Mortensen, S. A., and Quistorff, B. No effect of antioxidant supplementation in triathletes on maximal oxygen uptake, 31P-NMRS detected muscle energy metabolism and muscle fatigue. Int J Sports Med 1999;20(3):154-158. View abstract.
  • Niklowitz, P., Sonnenschein, A., Janetzky, B., Andler, W., and Menke, T. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage. Int J Biol Sci 2007;3(4):257-262. View abstract.
  • Nishino, M., Usami, M., Sugimura, S., and Yoshizaki, S. [Case of drug-induced pneumonitis associated with a dietary supplement containing CoQ10]. Nihon Kokyuki.Gakkai Zasshi 2006;44(10):766-770. View abstract.
  • Oda T. Coenzyme Q10 therapy on the cardiac dysfunction in patients with mitral valve prolapse: dose vs effect and dose vs serum level of coenzyme Q10. In: Folkers K and Yamamura Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier Science;1986.
  • Oda T. Dose-effect relationship and critical dose of coenzyme Q10 on load-induced cardiac dysfunction in pediatric patients with mitral valve prolapse. In: Folkers K, Littarru GP and Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier Science;1991.
  • Oda T. Effect of coenzyme Q10 on load-induced cardiac dysfunction: double blind study and investigation of dose-response relationship. In: Lenaz G, Barnabei O Rabbi A and et al. Highlights in Ubiquinone Research. London: Taylor and Francis;1990.
  • Oda, T. and Hamamoto, K. Effect of coenzyme Q10 on the stress-induced decrease of cardiac performance in pediatric patients with mitral valve prolapse. Jpn.Circ.J 1984;48(12):1387. View abstract.
  • Oda, T. Effect of coenzyme Q10 on stress-induced cardiac dysfunction in paediatric patients with mitral valve prolapse: a study by stress echocardiography. Drugs Exp.Clin Res 1985;11(8):557-576. View abstract.
  • Oda, T. Recovery of load-induced left ventricular diastolic dysfunction by coenzyme Q10: echocardiographic study. Mol.Aspects Med 1994;15 Suppl:s149-s154. View abstract.
  • Oda, T. Recovery of the systolic time intervals by coenzyme Q10 in patients with a load-induced cardiac dysfunction. Mol.Aspects Med 1997;18 Suppl:S153-S158. View abstract.
  • Ogasahara, S., Nishikawa, Y., Yorifuji, S., Soga, F., Nakamura, Y., Takahashi, M., Hashimoto, S., Kono, N., and Tarui, S. Treatment of Kearns-Sayre syndrome with coenzyme Q10. Neurology 1986;36(1):45-53. View abstract.
  • Ogasahara, S., Yorifuji, S., Nishikawa, Y., Takahashi, M., Wada, K., Hazama, T., Nakamura, Y., Hashimoto, S., Kono, N., and Tarui, S. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology 1985;35(3):372-377. View abstract.
  • Okamura, T., Sunamori, M., Amano, J., Hirooka, Y., Ozeki, M., Tanaka, A., and Suzuki, A. Combined treatment of coenzyme Q10 and aprotinin with intraaortic balloon pumping following aorto-coronary bypass surgery. Jpn.J Surg 1984;14(2):97-103. View abstract.
  • Okuma, K., Furuta, I., and Ota, K. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin]. Gan To Kagaku Ryoho 1984;11(3):502-508. View abstract.
  • Okuyama, S. and Mishina, H. Principia of cancer therapy. VI. Application of ubiquinone ointment for intractable radiation ulcers: an expanded cytochrome C effect? Sci Rep.Res Inst.Tohoku Univ [Med] 1983;30(1-4):36-39. View abstract.
  • Orsucci, D., Filosto, M., Siciliano, G., and Mancuso, M. Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction. Nutr Rev. 2009;67(8):427-438. View abstract.
  • Ozaki, A., Muromachi, A., Sumi, M., Sakai, Y., Morishita, K., and Okamoto, T. Emulsification of coenzyme Q10 using gum arabic increases bioavailability in rats and human and improves food-processing suitability. J Nutr Sci Vitaminol.(Tokyo) 2010;56(1):41-47. View abstract.
  • Palacka, P., Kucharska, J., Murin, J., Dostalova, K., Okkelova, A., Cizova, M., Waczulikova, I., Moricova, S., and Gvozdjakova, A. Complementary therapy in diabetic patients with chronic complications: a pilot study. Bratisl.Lek.Listy 2010;111(4):205-211. View abstract.
  • Palomaki, A., Malminiemi, K., Solakivi, T., and Malminiemi, O. Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo. J Lipid Res 1998;39(7):1430-1437. View abstract.
  • Pandolfo, M. Introduction. Idebenone in the treatment of Friedreich ataxia. J Neurol. 2009;256 Suppl 1:1-2. View abstract.
  • Papas, K. A., Sontag, M. K., Pardee, C., Sokol, R. J., Sagel, S. D., Accurso, F. J., and Wagener, J. S. A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. J Cyst.Fibros. 2008;7(1):60-67. View abstract.
  • Parashos, S. A., Swearingen, C. J., Biglan, K. M., Bodis-Wollner, I., Liang, G. S., Ross, G. W., Tilley, B. C., and Shulman, L. M. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009;66(9):1099-1104. View abstract.
  • Patchett, D. C. and Grover, M. L. Mitochondrial myopathy presenting as rhabdomyolysis. J Am Osteopath.Assoc. 2011;111(6):404-405. View abstract.
  • Patel, B. P. and Hamadeh, M. J. Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clin Nutr. 2009;28(6):604-617. View abstract.
  • Pepe, S., Leong, J. Y., Van der Merwe, J., Marasco, S. F., Hadj, A., Lymbury, R., Perkins, A., and Rosenfeldt, F. L. Targeting oxidative stress in surgery: effects of ageing and therapy. Exp.Gerontol. 2008;43(7):653-657. View abstract.
  • Pfeffer, G., Majamaa, K., Turnbull, D. M., Thorburn, D., and Chinnery, P. F. Treatment for mitochondrial disorders. Cochrane Database.Syst.Rev. 2012;4:CD004426. View abstract.
  • Pineda, M., Arpa, J., Montero, R., Aracil, A., Dominguez, F., Galvan, M., Mas, A., Martorell, L., Sierra, C., Brandi, N., Garcia-Arumi, E., Rissech, M., Velasco, D., Costa, J. A., and Artuch, R. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr.Neurol. 2008;12(6):470-475. View abstract.
  • Pineda, M., Montero, R., Aracil, A., O'Callaghan, M. M., Mas, A., Espinos, C., Martinez-Rubio, D., Palau, F., Navas, P., Briones, P., and Artuch, R. Coenzyme Q(10)-responsive ataxia: 2-year-treatment follow-up. Mov Disord. 7-15-2010;25(9):1262-1268. View abstract.
  • Pogessi L, Galanti G, Corneglio M, and et al. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. Curr Ther Res 1991;49 :878-886.
  • Porter, D. A., Costill, D. L., Zachwieja, J. J., Krzeminski, K., Fink, W. J., Wagner, E., and Folkers, K. The effect of oral coenzyme Q10 on the exercise tolerance of middle- aged, untrained men. Int J Sports Med 1995;16(7):421-427. View abstract.
  • Premkumar, V. G., Yuvaraj, S., Sathish, S., Shanthi, P., and Sachdanandam, P. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul.Pharmacol. 2008;48(4-6):191-201. View abstract.
  • Prieme, H., Loft, S., Nyyssonen, K., Salonen, J. T., and Poulsen, H. E. No effect of supplementation with vitamin E, ascorbic acid, or coenzyme Q10 on oxidative DNA damage estimated by 8-oxo-7,8-dihydro-2'- deoxyguanosine excretion in smokers. Am J Clin Nutr 1997;65(2):503-507. View abstract.
  • Rakoczi, K., Klivenyi, P., and Vecsei, L. [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings]. Ideggyogy.Sz 1-30-2009;62(1-2):25-34. View abstract.
  • Ramelli, G. P., Gallati, S., Weis, J., Krahenbuhl, S., and Burgunder, J. M. Point mutation tRNA(Ser(UCN)) in a child with hearing loss and myoclonus epilepsy. J Child Neurol. 2006;21(3):253-255. View abstract.
  • Ramirez-Tortosa, M. C., Quiles, J. L., Battino, M., Granados, S., Morillo, J. M., Bompadre, S., Newman, H. N., and Bullon, P. Periodontitis is associated with altered plasma fatty acids and cardiovascular risk markers. Nutr Metab Cardiovasc.Dis 2010;20(2):133-139. View abstract.
  • Ranen, N. G., Peyser, C. E., Coyle, J. T., Bylsma, F. W., Sherr, M., Day, L., Folstein, M. F., Brandt, J., Ross, C. A., and Folstein, S. E. A controlled trial of idebenone in Huntington's disease. Mov Disord. 1996;11(5):549-554. View abstract.
  • Rastogi SS, Singh RB, and Shukla PK. Randomized, double blind, placebo controlled trial of hydrosoluble coenzyme Q10 in patients with hyperinsulinemia. First Conference of the International Coenzyme Q10 Association 2002;
  • Ravina, B., Romer, M., Constantinescu, R., Biglan, K., Brocht, A., Kieburtz, K., Shoulson, I., and McDermott, M. P. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord. 7-15-2008;23(9):1223-1227. View abstract.
  • Reid, M. S., Casadonte, P., Baker, S., Sanfilipo, M., Braunstein, D., Hitzemann, R., Montgomery, A., Majewska, D., Robinson, J., and Rotrosen, J. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100 Suppl 1:43-57. View abstract.
  • Rinaldi, C., Tucci, T., Maione, S., Giunta, A., De, Michele G., and Filla, A. Low-dose idebenone treatment in Friedreich's ataxia with and without cardiac hypertrophy. J Neurol. 2009;256(9):1434-1437. View abstract.
  • Roberts J. The effects of coenzyme Q10 on excercise performance. Med Sci Sports Exerc 1990;22((suppl)):S87.
  • Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., and Tarnopolsky, M. A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35(2):235-242. View abstract.
  • Rodriguez-Hernandez, A., Cordero, M. D., Salviati, L., Artuch, R., Pineda, M., Briones, P., Gomez, Izquierdo L., Cotan, D., Navas, P., and Sanchez-Alcazar, J. A. Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. Autophagy. 1-1-2009;5(1):19-32. View abstract.
  • Roland, L., Gagne, A., Belanger, M. C., Boutet, M., Berthiaume, L., Fraser, W. D., Julien, P., and Bilodeau, J. F. Existence of compensatory defense mechanisms against oxidative stress and hypertension in preeclampsia. Hypertens.Pregnancy. 2010;29(1):21-37. View abstract.
  • Rosenfeldt, F. L., Haas, S. J., Krum, H., Hadj, A., Ng, K., Leong, J. Y., and Watts, G. F. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum.Hypertens. 2007;21(4):297-306. View abstract.
  • Rosenfeldt, F. L., Pepe, S., Linnane, A., Nagley, P., Rowland, M., Ou, R., Marasco, S., and Lyon, W. The effects of ageing on the response to cardiac surgery: protective strategies for the ageing myocardium. Biogerontology. 2002;3(1-2):37-40. View abstract.
  • Rosenfeldt, F., Marasco, S., Lyon, W., Wowk, M., Sheeran, F., Bailey, M., Esmore, D., Davis, B., Pick, A., Rabinov, M., Smith, J., Nagley, P., and Pepe, S. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac.Cardiovasc.Surg. 2005;129(1):25-32. View abstract.
  • Rusciani, L., Proietti, I., Paradisi, A., Rusciani, A., Guerriero, G., Mammone, A., De Gaetano, A., and Lippa, S. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up. Melanoma Res 2007;17(3):177-183. View abstract.
  • Rusciani, L., Proietti, I., Rusciani, A., Paradisi, A., Sbordoni, G., Alfano, C., Panunzi, S., De Gaetano, A., and Lippa, S. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 2006;54(2):234-241. View abstract.
  • Ryo, K., Ito, A., Takatori, R., Tai, Y., Arikawa, K., Seido, T., Yamada, T., Shinpo, K., Tamaki, Y., Fujii, K., Yamamoto, Y., and Saito, I. Effects of coenzyme Q10 on salivary secretion. Clin Biochem 2011;44(8-9):669-674. View abstract.
  • Sacconi, S., Trevisson, E., Salviati, L., Ayme, S., Rigal, O., Redondo, A. G., Mancuso, M., Siciliano, G., Tonin, P., Angelini, C., Aure, K., Lombes, A., and Desnuelle, C. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul.Disord. 2010;20(1):44-48. View abstract.
  • Sacher, H. L., Sacher, M. L., Landau, S. W., Kersten, R., Dooley, F., Sacher, A., Sacher, M., Dietrick, K., and Ichkhan, K. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. Am J Ther 1997;4(2-3):66-72. View abstract.
  • Safarinejad, M. R. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie's disease: a double-blind, placebo-controlled randomized study. Int J Impot.Res 2010;22(5):298-309. View abstract.
  • Sagel, S. D., Sontag, M. K., Anthony, M. M., Emmett, P., and Papas, K. A. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J Cyst.Fibros. 10-18-2010; View abstract.
  • Sakata, T., Furuya, R., Shimazu, T., Odamaki, M., Ohkawa, S., and Kumagai, H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008;26(4):371-378. View abstract.
  • Salami, A., Mora, R., Dellepiane, M., Manini, G., Santomauro, V., Barettini, L., and Guastini, L. Water-soluble coenzyme Q10 formulation (Q-TER((R))) in the treatment of presbycusis. Acta Otolaryngol. 2010;130(10):1154-1162. View abstract.
  • Salles, J. E., Moises, V. A., Almeida, D. R., Chacra, A. R., and Moises, R. S. Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. Diabetes Res Clin Pract 2006;72(1):100-103. View abstract.
  • Salviati, L., Sacconi, S., Murer, L., Zacchello, G., Franceschini, L., Laverda, A. M., Basso, G., Quinzii, C., Angelini, C., Hirano, M., Naini, A. B., Navas, P., DiMauro, S., and Montini, G. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 8-23-2005;65(4):606-608. View abstract.
  • Santa-Mara, I., Santpere, G., MacDonald, M. J., Gomez de, Barreda E., Hernandez, F., Moreno, F. J., Ferrer, I., and Avila, J. Coenzyme q induces tau aggregation, tau filaments, and Hirano bodies. J Neuropathol.Exp.Neurol. 2008;67(5):428-434. View abstract.
  • Satta, A., Grandi, M., Landoni, C. V., Migliori, G. B., Spanevello, A., Vocaturo, G., and Neri, M. Effects of ubidecarenone in an exercise training program for patients with chronic obstructive pulmonary diseases. Clin Ther. 1991;13(6):754-757. View abstract.
  • Scaglione F, Lundstrom B, Barbieri B, and et al. Coenzyme Q10 as an immunoenhancer. A single blind placebo-controlled and randomized clinical study [abstract]. First Conference of the International Coenzyme Q10 Association 1998;
  • Scarlato, G., Bresolin, N., Moroni, I., Doriguzzi, C., Castelli, E., Comi, G., Angelini, C., and Carenzi, A. Multicenter trial with ubidecarenone: treatment of 44 patients with mitochondrial myopathies. Rev Neurol.(Paris) 1991;147(6-7):542-548. View abstract.
  • Schardt F, Welzel D, Scheiss W, and et al. Effect of coenzyme Q10 on ischemia-induced ST-segment depression: a double-blind, placebo-controlled, crossover study. In: Folkers, K and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q10. Amsterdam: Elsevier;1985.
  • Schiapparelli, P., Allais, G., Castagnoli, Gabellari, I, Rolando, S., Terzi, M. G., and Benedetto, C. Non-pharmacological approach to migraine prophylaxis: part II. Neurol.Sci. 2010;31 Suppl 1:S137-S139. View abstract.
  • Schmitz-Hubsch, T. and Klockgether, T. An update on inherited ataxias. Curr Neurol.Neurosci.Rep. 2008;8(4):310-319. View abstract.
  • Schneeberger, W., Muller-Steinwachs, J., Anda, L. P., Fuchs, W., Zilliken, F., Lyson, K., Muratsu, K., and Folkers, K. A clinical double-blind and crossover trial with coenzyme Q10 on patients with cardiac disease. In: Folkers, K. and Yamamura, Y. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier;1986.
  • Schulz, C., Obermuller-Jevic, U. C., Hasselwander, O., Bernhardt, J., and Biesalski, H. K. Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10). Int J Food Sci Nutr 2006;57(7-8):546-555. View abstract.
  • Schulz, J. B., Di Prospero, N. A., and Fischbeck, K. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol. 2009;256 Suppl 1:42-45. View abstract.
  • Senes, M., Erbay, A. R., Yilmaz, F. M., Topkaya, B. C., Zengi, O., Dogan, M., and Yucel, D. Coenzyme Q10 and high-sensitivity C-reactive protein in ischemic and idiopathic dilated cardiomyopathy. Clin Chem.Lab Med 2008;46(3):382-386. View abstract.
  • Servidei S, Spinazzola A, Crociani P, and et al. Replacement therapy is effective in familial mitochondrial encephalomyopathy with muscle coenzyme Q10 deficiency. Neurology 1996;46:A420.
  • Shilov, A. M., Mel'nik, M. V., Voevodina, E. S., Osiia, A. O., and Griaznov, D. A. [Prophylaxis of ischemic heart lesions during chronic heart failure with complex therapy using Q10 coenzyme]. Anesteziol.Reanimatol. 2011;(2):34-38. View abstract.
  • Shojaei, M., Djalali, M., Khatami, M., Siassi, F., and Eshraghian, M. Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy. Iran J Kidney Dis 2011;5(2):114-118. View abstract.
  • Shults, C. W., Flint, Beal M., Song, D., and Fontaine, D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp.Neurol. 2004;188(2):491-494. View abstract.
  • Shults, C. W., Haas, R. H., and Beal, M. F. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors 1999;9(2-4):267-272. View abstract.
  • Shults, C. W., Haas, R. H., Passov, D., and Beal, M. F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann.Neurol. 1997;42(2):261-264. View abstract.
  • Sieswerda, E., van Dalen, E. C., Postma, A., Cheuk, D. K., Caron, H. N., and Kremer, L. C. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst.Rev. 2011;(9):CD008011. View abstract.
  • Silver, M. A., Langsjoen, P. H., Szabo, S., Patil, H., and Zelinger, A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 11-15-2004;94(10):1306-1310. View abstract.
  • Simonenko, V. B., Stepaniants, O. S., and Teslia, A. N. [Myocardial cytoprotectors, a reserve therapeutic modality for patients with stable angina of effort]. Klin.Med (Mosk) 2011;89(4):34-36. View abstract.
  • Sinatra, S. T. Coenzyme Q10 and congestive heart failure. Ann.Intern.Med 11-7-2000;133(9):745-746. View abstract.
  • Sinatra, S. T. Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern.Ther Health Med. 2009;15(3):44-52. View abstract.
  • Sinatra, S. T. Refractory congestive heart failure successfully managed with high dose coenzyme Q10 administration. Mol.Aspects Med 1997;18 Suppl:S299-S305. View abstract.
  • Singh RB, Khanna HK, and Niaz MA. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role. J Nutr Environ Med 2000;10:281-288.
  • Singh, R. B., Kartikey, K., Charu, A. S., Niaz, M. A., and Schaffer, S. Effect of taurine and coenzyme Q10 in patients with acute myocardial infarction. Adv.Exp.Med.Biol. 2003;526:41-48. View abstract.
  • Singh, R. B., Niaz, M. A., Kumar, A., Sindberg, C. D., Moesgaard, S., and Littarru, G. P. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors 2005;25(1-4):219-224. View abstract.
  • Singh, R. B., Wander, G. S., Rastogi, A., Shukla, P. K., Mittal, A., Sharma, J. P., Mehrotra, S. K., Kapoor, R., and Chopra, R. K. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc.Drugs Ther. 1998;12(4):347-353. View abstract.
  • Sival, D. A., du Marchie Sarvaas, G. J., Brouwer, O. F., Uges, D. R., Verschuuren-Bemelmans, C. C., Maurits, N. M., Brunt, E. R., and van der Hoeven, J. H. Neurophysiological evaluation in children with Friedreich's ataxia. Early Hum.Dev. 2009;85(10):647-651. View abstract.
  • Sivitz, W. I. and Yorek, M. A. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid.Redox.Signal. 2010;12(4):537-577. View abstract.
  • Skough, K., Krossen, C., Heiwe, S., Theorell, H., and Borg, K. Effects of resistance training in combination with coenzyme Q10 supplementation in patients with post-polio: a pilot study. J Rehabil.Med 2008;40(9):773-775. View abstract.
  • Slater, S. K., Nelson, T. D., Kabbouche, M. A., Lecates, S. L., Horn, P., Segers, A., Manning, P., Powers, S. W., and Hershey, A. D. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011;31(8):897-905. View abstract.
  • Snider, I. P., Bazzarre, T. L., Murdoch, S. D., and Goldfarb, A. Effects of coenzyme athletic performance system as an ergogenic aid on endurance performance to exhaustion. Int J Sport Nutr 1992;2(3):272-286. View abstract.
  • Someya, S., Xu, J., Kondo, K., Ding, D., Salvi, R. J., Yamasoba, T., Rabinovitch, P. S., Weindruch, R., Leeuwenburgh, C., Tanokura, M., and Prolla, T. A. Age-related hearing loss in C57BL/6J mice is mediated by Bak-dependent mitochondrial apoptosis. Proc.Natl.Acad.Sci U.S.A 11-17-2009;106(46):19432-19437. View abstract.
  • Soukoulis, V., Dihu, J. B., Sole, M., Anker, S. D., Cleland, J., Fonarow, G. C., Metra, M., Pasini, E., Strzelczyk, T., Taegtmeyer, H., and Gheorghiade, M. Micronutrient deficiencies an unmet need in heart failure. J Am Coll.Cardiol. 10-27-2009;54(18):1660-1673. View abstract.
  • Spurney, C. F., Rocha, C. T., Henricson, E., Florence, J., Mayhew, J., Gorni, K., Pasquali, L., Pestronk, A., Martin, G. R., Hu, F., Nie, L., Connolly, A. M., and Escolar, D. M. CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve 2011;44(2):174-178. View abstract.
  • Stacpoole, P. W., DeGrauw, T. J., Feigenbaum, A. S., Hoppel, C., Kerr, D. S., McCandless, S. E., Miles, M. V., Robinson, B. H., and Tang, P. H. Design and implementation of the first randomized controlled trial of coenzyme CoQ(1)(0) in children with primary mitochondrial diseases. Mitochondrion. 2012;12(6):623-629. View abstract.
  • Stamelou, M., Reuss, A., Pilatus, U., Magerkurth, J., Niklowitz, P., Eggert, K. M., Krisp, A., Menke, T., Schade-Brittinger, C., Oertel, W. H., and Hoglinger, G. U. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 5-15-2008;23(7):942-949. View abstract.
  • Stocker, R., Bowry, V. W., and Frei, B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl.Acad Sci U.S.A 3-1-1991;88(5):1646-1650. View abstract.
  • Storch, A. [Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?]. Nervenarzt 2007;78(12):1378-1382. View abstract.
  • Strijks, E., Kremer, H. P., and Horstink, M. W. Q10 therapy in patients with idiopathic Parkinson's disease. Mol.Aspects Med. 1997;18 Suppl:S237-S240. View abstract.
  • Strong, M. J. and Pattee, G. L. Creatine and coenzyme Q10 in the treatment of ALS. Amyotroph.Lateral.Scler.Other Motor Neuron Disord 2000;1(suppl 4):17-20. View abstract.
  • Sun, H. Y. [Clinical study of Wenxikeli treatment of viral myocarditis]. Zhonghua Shi Yan.He.Lin.Chuang.Bing.Du Xue.Za Zhi. 2009;23(2):144-145. View abstract.
  • Sunamori, M., Tanaka, H., Maruyama, T., Sultan, I., Sakamoto, T., and Suzuki, A. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization. Cardiovasc.Drugs Ther 1991;5 Suppl 2:297-300. View abstract.
  • Suzuki, H., Naitoh, T., Kuniyoshi, S., Banba, N., Kuroda, H., Suzuki, Y., Hiraiwa, M., Yamazaki, N., Ishikawa, M., Hashigami, Y., and . Cardiac performance and coenzyme Q10 in thyroid disorders. Endocrinol Jpn. 1984;31(6):755-761. View abstract.
  • Suzuki, Y., Kadowaki, H., Atsumi, Y., Hosokawa, K., Katagiri, H., Kadowaki, T., Oka, Y., Uyama, K., Mokubo, A., Asahina, T., and . A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation and successful therapy with coenzyme Q10. Endocr.J 1995;42(2):141-145. View abstract.
  • Suzuki, Y., Taniyama, M., Muramatsu, T., Atsumi, Y., Hosokawa, K., Asahina, T., Shimada, A., Murata, C., and Matsuoka, K. Diabetes mellitus associated with 3243 mitochondrial tRNA(Leu(UUR)) mutation: clinical features and coenzyme Q10 treatment. Mol.Aspects Med 1997;18 Suppl:S181-S188. View abstract.
  • Syrkin A, Kogan A, Drynitsina S, and et al. The effect of soluble form of coenzyme Q10 on the oxygen free radical processes and clinical course in patients with coronary heart disease - stable angina pectoris. First Conference of the International Coenzyme Q10 Association 2002;
  • Tajima, M. [Chronic cardiotoxicity of anthracycline derivatives and possible prevention by coenzyme Q10]. Gan No Rinsho 1984;30(9 Suppl):1211-1216. View abstract.
  • Takimoto, M., Sakurai, T., Kodama, K., Yokoi, H., Suzuki, Y., Enomoto, K., and Okada, N. [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy]. Gan To Kagaku Ryoho 1982;9(1):116-121. View abstract.
  • Tanaka, J., Tominaga, R., Yoshitoshi, M., Matsui, K., Komori, M., Sese, A., Yasui, H., and Tokunaga, K. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann.Thorac.Surg. 1982;33(2):145-151. View abstract.
  • Tang, K. F., Xing, Y., Wu, C. Y., Liu, R. Z., Wang, X. Y., and Xing, J. P. [Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia]. Zhonghua Nan.Ke.Xue. 2011;17(7):615-618. View abstract.
  • Tauler, P., Ferrer, M. D., Sureda, A., Pujol, P., Drobnic, F., Tur, J. A., and Pons, A. Supplementation with an antioxidant cocktail containing coenzyme Q prevents plasma oxidative damage induced by soccer. Eur J Appl.Physiol 2008;104(5):777-785. View abstract.
  • Tawankanjanachot, I., Channarong, N. S., and Phanthumchinda, K. Auditory symptoms: a critical clue for diagnosis of MELAS. J Med Assoc Thai. 2005;88(11):1715-1720. View abstract.
  • Teerlink T, Musch EE, Baker SJL, and et al. Resistance of low density lipoprotein against in vitro oxidation is associated with its coenzyme Q10 content in type 2 diabetes. First Conference of the International Coenzyme Q10 Association 2002;
  • Teran, E., Chedraui, P., Racines-Orbe, M., Vivero, S., Villena, F., Duchicela, F., Nacevilla, L., Schwager, G., and Calle, A. Coenzyme Q10 levels in women with preeclampsia living at different altitudes. Biofactors 2008;32(1-4):185-190. View abstract.
  • Thomas, B. and Beal, M. F. Mitochondrial therapies for Parkinson's disease. Mov Disord. 2010;25 Suppl 1:S155-S160. View abstract.
  • Tiano, L., Belardinelli, R., Carnevali, P., Principi, F., Seddaiu, G., and Littarru, G. P. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur.Heart J 2007;28(18):2249-2255. View abstract.
  • Tomasetti, M., Alleva, R., Solenghi, M. D., and Littarru, G. P. Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. Biofactors 1999;9(2-4):231-240. View abstract.
  • Tomono, Y., Hasegawa, J., Seki, T., Motegi, K., and Morishita, N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int J Clin Pharmacol Ther.Toxicol 1986;24(10):536-541. View abstract.
  • Tonon, C. and Lodi, R. Idebenone in Friedreich's ataxia. Expert.Opin.Pharmacother. 2008;9(13):2327-2337. View abstract.
  • Traber, G., Baumgartner, M. R., Schwarz, U., Pangalu, A., Donath, M. Y., and Landau, K. Subacute bilateral visual loss in methylmalonic acidemia. J Neuroophthalmol. 2011;31(4):344-346. View abstract.
  • Tsou, A. Y., Friedman, L. S., Wilson, R. B., and Lynch, D. R. Pharmacotherapy for Friedreich ataxia. CNS.Drugs 2009;23(3):213-223. View abstract.
  • Tsubaki, K., Horiuchi, A., Kitani, T., Taniguchi, N., Masaoka, T., Shibata, H., Yonezawa, T., Tsubakio, T., Kawagoe, H., Shinohara, Y., and . [Investigation of the preventive effect of CoQ10 against the side- effects of anthracycline antineoplastic agents]. Gan To Kagaku Ryoho 1984;11(7):1420-1427. View abstract.
  • Tsujita, Y., Kunitomo, T., Fujii, M., Furukawa, S., Otsuki, H., Fujino, K., Hamamoto, T., Tabata, T., Matsumura, K., Sasaki, T., Saotome, T., Kawai, H., Matsumoto, T., Maeda, K., Horie, M., and Eguchi, Y. A surviving case of mitochondrial cardiomyopathy diagnosed from the symptoms of multiple organ dysfunction syndrome. Int J Cardiol. 8-1-2008;128(1):e43-e45. View abstract.
  • Tsuyama, Y., Adachi-Usami, E., and Takeda, N. A case of Kearns-Shy syndrome with later onset. Ophthalmologica 1993;206(3):149-151. View abstract.
  • Udompataikul, M., Sripiroj, P., and Palungwachira, P. An oral nutraceutical containing antioxidants, minerals and glycosaminoglycans improves skin roughness and fine wrinkles. Int.J Cosmet.Sci 2009;31(6):427-435. View abstract.
  • Ursini T. Coenzyme Q10 treatment of heart failure in the elderly: preliminary results. In: Folkers K, Littarru GP and Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier;1991.
  • van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev 2005;(1):CD003917. View abstract.
  • van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev. 2008;(2):CD003917. View abstract.
  • van Dalen, E. C., Caron, H. N., Dickinson, H. O., and Kremer, L. C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane.Database.Syst.Rev. 2011;(6):CD003917. View abstract.
  • van Gaal L, Folkers K and Yamamura Y. Exploratory study of coenzyme Q10 in obesity. In: Folkers K and Yamura Y. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier Science Publications;1984.
  • Vitetta, L., Sali, A., and Reavley, N. J. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 10-15-2001;175(8):447-448. View abstract.
  • Voronkova, K. V. and Meleshkov, M. N. [Noben (idebenone) in the treatment of dementia and memory impairment without dementia]. Zh.Nevrol.Psikhiatr.Im S.S.Korsakova 2008;108(4):27-32. View abstract.
  • Voronkova, K. V. and Meleshkov, M. N. Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia. Neurosci.Behav.Physiol 2009;39(5):501-506. View abstract.
  • Wahlqvist ML, Wattanapenpaiboon N, Savige GS, and et al. Bioavailability of two different formulations of coenzyme Q10 in healthy subjects. Asia Pac J Clin Nutr 1998;7(1):37-40.
  • Wander GS, Singh RB, and Shukla PK. Randomized double blind trial of hydrosoluble coenzyme Q10 in hypertensives with oxidative stress and coronary artery disease. First Conference of the International Coenzyme Q10 Association 2002;
  • Wang, S. B., Weng, W. C., Lee, N. C., Hwu, W. L., Fan, P. C., and Lee, W. T. Mutation of mitochondrial DNA G13513A presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr.Neonatol. 2008;49(4):145-149. View abstract.
  • Watson, P. S., Scalia, G. M., Gaibraith, A. J., Burstow, D. J., Aroney, C. N., and Bett, J. H. Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy? Med J Aust. 10-15-2001;175(8):447-448. View abstract.
  • Weber C, Bysted A, and Holmer G. Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects. Nutrition Research 1997;17(6):941-945.
  • Weber M, Andler W, Enzmann F, and et al. Increased oxidative stress in glycogen storage disease type IB: preliminary results of an antioxidative treatment with coenzyme Q10, selenium and ascorbic acid. First Conference of the International Coenzyme Q10 Association 2002;
  • Weber, C., Bysted, A., and Holmer, G. Coenzyme Q10 in the diet--daily intake and relative bioavailability. Mol.Aspects Med 1997;18 Suppl:S251-S254. View abstract.
  • Weber, C., Jakobsen, T. S., Mortensen, S. A., Paulsen, G., and Holmer, G. Effect of dietary coenzyme Q10 as an antioxidant in human plasma. Mol.Aspects Med 1994;15 Suppl:s97-s102. View abstract.
  • Weber, C., Sejersgard, Jakobsen T., Mortensen, S. A., Paulsen, G., and Holmer, G. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. Int J Vitam.Nutr Res 1994;64(4):311-315. View abstract.
  • Wilkinson EG, Arnold RM, Folkers K, and et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Research Communications in Chemical Pathology and Pharmacology 1975;12(1):111-124.
  • Witte, K. K., Nikitin, N. P., Parker, A. C., von Haehling, S., Volk, H. D., Anker, S. D., Clark, A. L., and Cleland, J. G. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005;26(21):2238-2244. View abstract.
  • Wyss V, Lubich T Ganzit GP Cesaretti D Fiorella PL Dei C Rocini C Bargossi AM Battistoni R Lippi A Grossi G Sprovieri G Battino M. Remarks on prolonged ubiquinone administration in physical exercise. Highlights in Ubiquinone Research 1990;303-308.
  • Yamagami T, Takagi M, Akagami H, and et al. Effect of coenzyme Q10 on essential hypertension: a double-blind controlled study. In: Folkers K and Yamamura Y. Biomedical and Clinical Aspects on Coenzyme Q. Amsterdam: Elsevier;1986.
  • Yamagami, T., Shibata, N., and Folkers, K. Bioenergetics in clinical medicine. Studies on coenzyme Q10 and essential hypertension. Res Commun Chem Pathol.Pharmacol 1975;11(2):273-288. View abstract.
  • Yamagami, T., Shibata, N., and Folkers, K. Bioenergetics in clinical medicine. VIII. Adminstration of coenzyme Q10 to patients with essential hypertension. Res Commun.Chem.Pathol.Pharmacol 1976;14(4):721-727. View abstract.
  • Yang, X., Dai, G., Li, G., and Yang, E. S. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease. J Mol.Neurosci. 2010;41(1):110-113. View abstract.
  • Yang, X., Yang, Y., Li, G., Wang, J., and Yang, E. S. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol.Neurosci. 2008;34(2):165-171. View abstract.
  • Yikoski T, Piirainen J, Hanninen O, and et al. The effect of coenzyme Q10 on the exercise performance of cross-country skiers. Molec Aspects Med 1997;18 Suppl:s283-s290.
  • Ylikoski, T., Piirainen, J., Hanninen, O., and Penttinen, J. The effect of coenzyme Q10 on the exercise performance of cross-country skiers. Mol.Aspects Med 1997;18 Suppl:S283-S290. View abstract.
  • Young JM, Florkowski CM Molyneux SL McEwan RG Frampton CM George PM. Coenzyme Q10 does not improve simvastatin tolerability in dyslipidemic patients with prior statin-induced myalgia. Circulation 2007;114:II41.
  • Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., Nicholls, M. G., Scott, R. S., and George, P. M. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndrome. Am J Hypertens. 2012;25(2):261-270. View abstract.
  • Yuvaraj, S., Premkumar, V. G., Vijayasarathy, K., Gangadaran, S. G., and Sachdanandam, P. Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin. Cancer Chemother.Pharmacol 2008;61(6):933-941. View abstract.
  • Zaffanello, M. and Zamboni, G. Therapeutic approach in a case of Pearson's syndrome. Minerva Pediatr 2005;57(3):143-146. View abstract.
  • Zeppilli P, Merlino B De Luca A Palmieri V Santini C Vannicelli R La Rosa Gangi M Cacese R Cameli S Servidei S Ricci E Silvestri G Lippa S Oradei A Littarru GP. Influence of coenzyme Q10 on physical work capacity in athletes, sedentary people and patients with mitochondrial disease. Biochemical and clinical aspects of Coenzyme Q10. 1991;6
  • Zheng, A. and Moritani, T. Influence of CoQ10 on autonomic nervous activity and energy metabolism during exercise in healthy subjects. J Nutr Sci Vitaminol.(Tokyo) 2008;54(4):286-290. View abstract.
  • Zhou, M., Zhi, Q., Tang, Y., Yu, D., and Han, J. Effects of coenzyme Q10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. J Cardiovasc.Surg.(Torino) 1999;40(3):355-361. View abstract.
  • Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors 2008;32:145-9. View abstract.
  • Alehagen U, Johansson P, Bjornstedt M, et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: A 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. Int J Cardiol 2013;167(5):1860-6. View abstract.
  • American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. Endocr Pract 2003;9:417-70. View abstract.
  • Andersen CB, Henriksen JE, Hother-Nielsen O, et al. The effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus. Mol Aspects Med 1997;18 Suppl:S307-9. View abstract.
  • Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 1992;56:95-9. View abstract.
  • Baggio E, Gandini R, Plauncher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994;15 Suppl:S287-94. View abstract.
  • Balercia G, Mosca F, Mantero F, et al. Coenzyme Q10 supplementation in infertile men with idiopathic asthenozoospermia: an open, uncontrolled pilot study. Fertil Steril 2004;81:93-8. View abstract.
  • Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015 Jan;90(1):24-34. doi: 10.1016/j.mayocp.2014.08.021. View abstract.
  • Bargossi AM, Grossi G, Fiorella PL, et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 1994;15:187-93. View abstract.
  • BBelardinelli R, Mucaj A, Lacalaprice F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006;27:2675-81. View abstract.
  • Belardinelli R, Muçaj A, Lacalaprice F, et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors 2005;25:137-45. View abstract.
  • Bentler, S. E., Hartz, A. J., and Kuhn, E. M. Prospective observational study of treatments for unexplained chronic fatigue. J Clin Psychiatry 2005;66(5):625-632. View abstract.
  • Berbel-Garcia A, Barbera-Farre JR, Etessam JP, ET AL. Coenzyme Q 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004;27:187-91. View abstract.
  • Berman M, Erman A, Ben-Gal T, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol 2004;27:295–9. View abstract.
  • Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 1993;111:761-72. View abstract.
  • Bertelli A, Cerrati A, Giovannini L, et al. Protective action of L-carnitine and coenzyme Q10 against hepatic triglyceride infiltration induced by hyperbaric oxygen and ethanol. Drugs Exp Clin Res 1993;19:65-8.. View abstract.
  • Bertelli A, Ronca G. Carnitine and coenzyme Q10: biochemical properties and functions, synergism and complementary action. Int J Tissue React 1990;12:183-6. View abstract.
  • Berthold HK, Naini A, Di Mauro S, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 2006;29:703-12. View abstract.
  • Bitensky L, Hart JP, Catterall A, et al. Circulating vitamin K levels in patients with fractures. J Bone Joint Surg Br 1988;70:663-4. View abstract.
  • Bleske BE, Willis RA, Anthony M, et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 2001;142:E2. View abstract.
  • Bogsrud MP, Langslet G, Ose L, et al. No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scand Cardiovasc J 2013;47(2):80-7. View abstract.
  • Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci 1998;156:41-6. View abstract.
  • Boles RG, Lovett-Barr MR, Preston A, et al. Treatment of cyclic vomiting syndrome with co-enzyme Q10 and amitriptyline, a retrospective study. BMC Neurol 2010;10:10. View abstract.
  • Bonetti A, Solito F, Carmosino G, et al. Effect of ubidecarenone oral treatment on aerobic power in middle-aged trained subjects. J Sports Med Phys Fitness 2000;40:51-7. View abstract.
  • Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990;100:70-8. View abstract.
  • Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001;94:1112-7. View abstract.
  • Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99:1409-12. View abstract.
  • Chan A, Reichmann H, Kogel A, et al. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245:681-5. View abstract.
  • Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann Thorac Surg 1994;58:1427-32. View abstract.
  • Chello M, Mastroroberto P, Romano R, et al. Protection by coenzyme Q10 of tissue reperfusion injury during abdominal aortic cross-clamping. J Cardiovasc Surg (Torino) 1996;37:229-35. View abstract.
  • Chen C, Zhou X-Z, Fan Y-M, et al. Clinical analysis of Sodium phosphocreatine on cardiac toxicity induced by anthracycline antibiotics in acute leukemia children [Unknown original title in Chinese]. Chinese Journal of Cancer Prevention and Treatment 2008;15(19):1503-5, 510.
  • Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997;37:212-8. View abstract.
  • Cordero MD, Alcocer-Gómez E, de Miguel M, et al. Can coenzyme Q10 improve clinical and molecular parameters in fibromyalgia? Antioxid Redox Signal. 2013;19(12):1356-61.
  • Cordero MD, Moreno-Fernandez AM, deMiguel M, et al. Coenzyme Q10 distribution in blood is altered in patients with fibromyalgia. Clin Biochem 2009;42:732-5. View abstract.
  • Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr 2001;20:591-8. View abstract.
  • De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA Reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-7. View abstract.
  • de Rijke YB, Bredie SJ, Demacker PN, et al. The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1997;17:127-33. View abstract.
  • Digiesi V, Cantini F, Oradei A, et al. Coenzyme Q10 in essential hypertension. Mol Aspects Med 1994;15 Suppl:s257-63. View abstract.
  • Eaton S, Skinner R, Hale JP, et al. Plasma coenzyme Q(10) in children and adolescents undergoing doxorubicin therapy. Clin Chim Acta 2000;302:1-9. View abstract.
  • Elsayed NM, Bendich A. Dietary antioxidants: potential effects on oxidative products in cigarette smoke. Nutr Res 2001;21:551-67.
  • Elshershari H, Ozer S, Ozkutlu S, Ozme S. Potential usefulness of coenzyme Q10 in the treatment of idiopathic dilated cardiomyopathy in children. Int J Cardiol 2003;88:101-2. View abstract.
  • Emmanuele V, López LC, Berardo A, et al. Heterogeneity of coenzyme Q10 deficiency. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol. 2012;69(8):978-83. View abstract.
  • Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost 2002;87:1075-6. View abstract.
  • Eriksson JG, Forsen TJ, Mortensen SA, Rohde M. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999;9:315-8. View abstract.
  • Fabbri A, Magrini N, Bianchi G, et al. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr 1996;20:159-64. View abstract.
  • FDA. List of Orphan Designations and Approvals. http://www.fda.gov/orphan/DESIGNAT/list.htm (Accessed 19 June 2004).
  • Fedacko J, Pella D, Fedackova P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharmacol 2013;91(2):165-70. View abstract.
  • Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996;11:321-3. View abstract.
  • Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002;22:1592-9.. View abstract.
  • Folkers K, Hanioka T, Xia LJ, et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 1991;176:786-91. View abstract.
  • Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment. Biochem Biophys Res Commun 1988;153:888-96. View abstract.
  • Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990;87:8931-4. View abstract.
  • Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochem Biophys Acta 1995;1271:281-6. View abstract.
  • Folkers K. Survey on the vitamin aspects of coenzyme Q. Int Z Vitaminforsch. 1969;39(3):334-52. View abstract.
  • Forester BP, Harper DG, Georgakas J, Ravichandran C, Madurai N, Cohen BM. Antidepressant effects of open label treatment with coenzyme Q10 in geriatric bipolar depression.J Clin Psychopharmacol. 2015 Jun;35(3):338-40. doi: 10.1097/JCP.0000000000000326. View abstract.
  • Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q(1)(0) supplementation on heart failure: a meta-analysis. Am.J.Clin.Nutr. 2013;97:268-75. View abstract.
  • Fuke C, Krikorian SA, Couris RR. Coenzyme Q10: A review of essential functions and clinical trials. US Pharm 2000;25:28-41.
  • Galasko D. R., Peskind E., Clark C. M., Quinn J. F., Ringman J. M., Jicha G. A., Cotman C., Cottrell B., Montine T. J., Thomas R. G., Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012;69(7):836-841. View abstract.
  • Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9. View abstract.
  • Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608. View abstract.
  • Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608. View abstract.
  • Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J Neural Transm 1998;54:301-10. View abstract.
  • Gvozdjáková A, Kucharská J, Ostatníková D, et al. Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longev. 2014;2014:798957. View abstract.
  • Hanaki Y, Sugiyama S, Ozawa T, et al. Coenzyme Q10 and coronary artery disease. Clin Investig 1993;71:112-5. View abstract.
  • Hanioka T, Tanaka M, Ojima M, et al. Effect of topical application of coenzyme Q10 on adult periodontitis. Molec Aspects Med 1994;15:S241-8. View abstract.
  • Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7. View abstract.
  • Henriksen JE, Andersen CB, Hother-Nielsen O, et al. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med 1999;16:312-8. View abstract.
  • Hershey AD, Powers SW, Vockell AB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent Migraine. Headache 2007;47:73-80. View abstract.
  • Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension (review). Cochrane Database Syst Rev 2009;(4):CD007435. View abstract.
  • Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2016 Mar 3;3:CD007435. doi: 10.1002/14651858.CD007435.pub3. View abstract.
  • Hodgson JM, Watts GF, Playford DA, et al. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002;56:1137-42. View abstract.
  • Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive treatment of congestive heart failure. J Card Fail 1995;1:101-7. View abstract.
  • Ishii N, Senoo-Matsuda N, Miyake K, et al. Coenzyme Q10 can prolong C. elegans lifespan by lowering oxidative stress. Mech Ageing Dev 2004;125:41-6. View abstract.
  • Iwamoto Y, Nakamura R, Folkers K, Morrison RF. Study of periodontal disease and coenzyme Q. Res Commun Chem Pathol Pharmacol 1975;11:265-71. View abstract.
  • Jolliet P, Simon N, Barre J, et al. Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences. Int J Clin Pharmacol Ther 1998;36:506-9. View abstract.
  • Joshi SS, Sawant SV, Shedge A, Halpner AD. Comparative bioavailability of two novel coenzyme Q10 preparations in humans. Int J Clin Pharmacol Ther 2003;41:42-8. View abstract.
  • Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247-51. View abstract.
  • Keogh A, Fenton S, Leslie C, et al. Randomised double-blind, placebo-controlled trial of coenzyme Q, therapy in class II and III systolic heart failure. Heart Lung Circ. 2003;12:135-41. View abstract.
  • Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636-40. View abstract.
  • Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001;19:81-3. View abstract.
  • Kishi H, Kishi T, Folkers K. Bioenergetics in clinical medicine. III. Inhibition of coenzyme Q10 enzymes by clinically used anti-hypertensive drugs. Res Commun Chem Pathol Pharmacol 1975;12:533-40. View abstract.
  • Kishi T, Makino K, Okamoto T, et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q. In: Yamamura Y, Folkers K, Ito Y (eds). Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier/North-Holland Biomedical Press 1980;2:139-54.
  • Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine. XV. Inhibition of coenzyme Q10 enzymes by clinically used adrenergic blockers of B-receptors. Res Commun Chem Pathol Pharmacol 1977;17:157-64. View abstract.
  • Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-6. View abstract.
  • Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clin Investig. 1993;71(8 Suppl):S129-33. View abstract.
  • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160:3226-7. View abstract.
  • Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994;S265-72. View abstract.
  • Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997;18 Suppl:S145-51. View abstract.
  • Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990;65:521-3. View abstract.
  • Langsjoen PH, Vadhanavikit S, Folkers K. Effective treatment with coenzyme Q10 of patients with chronic myocardial disease. Drugs Exp.Clin Res 1985;11:577-9. View abstract.
  • Lee CK, Pugh TD, Klopp RG, et al. The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice. Free Radic Biol Med 2004;36:1043-57. View abstract.
  • Lee YJ, Cho WJ, Kim JK, Lee DC. Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study. J Med Food 2011;14:386-90. View abstract.
  • Leong J. Y., van der Merwe J., Pepe S., Bailey M., Perkins A., Lymbury R., Esmore D., Marasco S., Rosenfeldt F. Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: a randomised trial. Heart Lung Circ 2010;19(10):584-591. View abstract.
  • Lerman-Sagie T, Rustin P, Lev D, et al. Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone. J Inherit Metab Dis 2001;24:28-34. View abstract.
  • Lesser GJ, Case D, Stark N, et al; Wake Forest University Community Clinical Oncology Program Research Base. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013;11(1):31-42. View abstract.
  • Lewin A, Lavon H. The effect of coenzyme Q10 on sperm motility and function. Mol Aspects Med 1997;18 Suppl:S213-9. View abstract.
  • Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J Int Med Res 2002;30:195-9. View abstract.
  • Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994;199:1504-8. View abstract.
  • Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995;212:172-7. View abstract.
  • Lonnrot K, Porsti I, Alho H, et al. Control of arterial tone after long-term coenzyme Q10 supplementation in senescent rats. Br J Pharmacol 1998;124:1500-6. View abstract.
  • Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PE. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol (Praha) 1998;43:505-6. View abstract.
  • Ma A, Zhang W, Liu Z. Effect of protection and repair of injury of mitochondrial membrane- phospholipid on prognosis in patients with dilated cardiomyopathy. Blood Press Suppl 1996;3:53-5. View abstract.
  • Malm C, Svensson M, Ekblom B, et al. Effects of ubiquinone-10 supplementation and high intensity training on physical performance in humans. Acta Physiol Scand 1997;161:379-84. View abstract.
  • Marcoff L, Thompson, PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49:2231-7. View abstract.
  • Morisco C, Nappi A, Argenziano L, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Mol.Aspects Med 1994;15 Suppl:s155-s63. View abstract.
  • Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term, multicenter, randomized study. Clin Investig 1993;71:S134-6. View abstract.
  • Mortensen SA, Kumar A, Dolliner P, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study. European Journal of Heart Failure 2013;15:S1-20.
  • Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18:S137-44. View abstract.
  • Mortensen SA, Vadhanavikit S, Muratsu K, Folkers K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12:155-62. View abstract.
  • Munkholm H., Hansen H. H., Rasmussen K. Coenzyme Q10 treatment in serious heart failure. Biofactors 1999;9:285-9. View abstract.
  • Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001;56:849-55. View abstract.
  • Nagao T, Ibayashi S, Fujii K, et al. Treatment of warfarin-induced hair loss with ubidecarenone. Lancet 1995;346:1104-5. View abstract.
  • Naylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989;97:1033-42. View abstract.
  • Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-52. View abstract.
  • Pepping J. Coenzyme Q10. Am J Health-Syst Pharm 1999;56:519-21. View abstract.
  • Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1528-33. View abstract.
  • Pizzorno JE, Murray MT, eds. Textbook of Natural Medicine. 2nd ed. New York: Churchill Livingston, 1999.
  • Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003;168:169-79. View abstract.
  • Portakal O, Ozkaya O, Erden Inal M, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33:279-84. View abstract.
  • Porterfield LM. Why did the response to warfarin change? RN 2000;63:107. View abstract.
  • Rengo F, Abete P, Landino P, et al. Role of metabolic therapy in cardiovascular disease. Clin Investig. 1993;71(8 Suppl):S124-S8. View abstract.
  • Robbers JE, Tyler VE. Tyler's Herbs of Choice: The Therapeutic Use of Phytomedicinals. New York, NY: The Haworth Herbal Press, 1999.
  • Rosenfeldt F., Hilton D., Pepe S., Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003;18:91-100. View abstract.
  • Rotig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000;356:391-5. View abstract.
  • Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-41. View abstract.
  • Rundek T, Naini A, Sacco R, et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol 2004;61:889-92.. View abstract.
  • Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. J Urol. 2012;188(2):526-31. View abstract.
  • Safarinejad MR, Shafiei N, Safarinejad S. Effects of EPA, ?-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial. Br J Nutr. 2013;110(1):164-71. View abstract.
  • Safarinejad MR. Efficacy of coenzyme Q-10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol 2009;182:237-48. View abstract.
  • Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail. 2006;12:464-72. View abstract.
  • Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64:713-5. View abstract.
  • Serra G, Lissoni F, Piemonti C, et al. Evaluation of coenzyme Q10 in patients with moderate heart failure and chronic stable effort angina. In: Folkers K, Littaru GP, and Yamagami T. Biomedical and clinical aspects of coenzyme Q. Amsterdam: Elsevier Science Publishers;1991.
  • Shanmugasundaram ER, Rajeswari G, Baskaran K, et al. Use of Gymnema sylvestre leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. J Ethnopharmacol 1990;30:281-94. View abstract.
  • Shoeibi A, Olfati N, Soltani Sabi M, Salehi M, Mali S, Akbari Oryani M. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg. 2017 Mar;117(1):103-109. doi: 10.1007/s13760-016-0697-z. View abstract.
  • Shults CW, Beal MF, Fontaine D, et al. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998;50:793-5. View abstract.
  • Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50. View abstract.
  • Singh RB, Neki NS, Kartikey K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 2003;246:75-82. View abstract.
  • Singh RB, Niaz MA, Rastogi SS, et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 1999;13:203-8. View abstract.
  • Skarlovnik A, Janic M, Lunder M, Turk M, Sabovic M. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study. Med Sci Monit. 2014 Nov 6;20:2183-8. doi: 10.12659/MSM.890777. View abstract.
  • Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48:1238-43. View abstract.
  • Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997;18:S159-68. View abstract.
  • Soongswang J, Sangtawesin C, Durongpisitkul K, et al. The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiol 2005;26:361-6. View abstract.
  • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;334:1372-3. View abstract.
  • Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 2007;64:938-44. View abstract.
  • Suzuki S, Hinokio Y, Ohtomo M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 1998;41:584-8. View abstract.
  • Taggart DP, Jenkins M, Hooper J, et al. Effects of short-term supplementation with coenzyme Q10 on myocardial protection during cardiac operations. Ann Thorac Surg 1996;61:829-33. View abstract.
  • Tang G, Serfaty-Lacrosniere C, Camilo ME, et al. Gastric acidity influences the blood response to a beta-carotene dose in humans. Am J Clin Nutr 1996;64:622-6. View abstract.
  • Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015 Feb;238(2):329-35. doi: 10.1016/j.atherosclerosis.2014.12.016. Epub 2014 Dec 17. View abstract.
  • Teran E, Hernandez I, Nieto B, et al. Coenzyme Q10 supplementation during pregnancy reduces the risk of pre-eclampsia. Int J Gynaecol Obstet 2009;105:43-5. View abstract.
  • The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404. View abstract.
  • The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8. View abstract.
  • Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91. View abstract.
  • Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. View abstract.
  • Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001;21:797-806. View abstract.
  • Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004;1660:171-99. View abstract.
  • Wang LW, Jabbour A, Hayward CS, Furlong TJ, Girgis L, Macdonald PS, et al. Potential role of coenzyme Q10 in facilitating recovery from statin-induced rhabdomyolysis. Intern Med J. 2015 Apr;45(4):451-3. doi: 10.1111/imj.12712. View abstract.
  • Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549-52. View abstract.
  • Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993;46:1055-7. View abstract.
  • Weis M, Mortensen SA, Rassing MR, et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 1994;15:s273-80. View abstract.
  • Welch KM. Current opinions in headache pathogenesis: introduction and synthesis. Curr Opin Neurol 1998;11:193-7. View abstract.
  • Weston SB, Zhou S, Weatherby RP, Robson SJ. Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes? Int J Sport Nutr 1997;7:197-206. View abstract.
  • Weyer G, Babej-Dolle RM, Hadler D, et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 1997;36:73-82. . View abstract.
  • Wilkinson EG, Arnold RM, Folkers K, et al. Bioenergetics in clinical medicine. II. Adjunctive treatment with coenzyme Q in periodontal therapy. Res Commun Chem Pathol Pharmacol 1975;12:111-23. View abstract.
  • Wilkinson EG, Arnold RM, Folkers K. Bioenergetics in clinical medicine. VI. Adjunctive treatment of periodontal disease with coenzyme Q10. Res Commun Chem Pathol Pharmacol 1976;14:715-9. View abstract.
  • Yamagami T, Takagi M, Akagami H, et al. Effect of coenzyme Q10 on essential hypertension, a double blind controlled study. In: Folkers KA, Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q, Vol. 5. Amsterdam: Elsevier Science Publications, 1986:337-43.
  • Zhao Q, Kebbati AH, Zhang Y, Tang Y, Okello E, Huang C. Effect of coenzyme Q10 on the incidence of atrial fibrillation in patients with heart failure. J Investig Med. 2015 Jun;63(5):735-9. doi: 10.1097/JIM.0000000000000202. View abstract.
  • Zhou Q, Chowbay B. Effect of coenzyme Q10 on the disposition of doxorubicin in rats. Eur J Drug Metab Pharmacokinet 2002;27:185-92. View abstract.
  • Zhu ZG, Sun MX, Zhang WL, Wang WW, Jin YM, Xie CL. The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. Neurol Sci 2017;38(2):215-224. View abstract.

More Resources for COENZYME Q10

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version. © Therapeutic Research Faculty 2009.